var title_f16_13_16592="Peripheral IV placement 6";
var content_f16_13_16592=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral IV placement: Completing insertion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Once the catheter is inserted, maintain pressure proximally to prevent bleeding and provide stability until IV tubing can be attached and the catheter secured.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Frank, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16592=[""].join("\n");
var outline_f16_13_16592=null;
var title_f16_13_16593="Short axis coronary artery TOF";
var content_f16_13_16593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1078px;\">",
"  <div class=\"videoplayer\" h264=\"./images/PEDS/63092/Short_axis_coro_art_TOF.mp4?title=Short+axis+coronary+artery+TOF\" style=\"width:432px;height:400px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Parasternal short axis view of coronary artery in tetralogy of Fallot (TOF)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This still frame from the accompanying echocardiographic video clip in the parasternal short axis window of a patient with tetralogy of Fallot (TOF) shows the left anterior descending (LAD) arising from the right coronary artery (RCA). This vessel courses anterior to the right ventricular outflow tract (RVOT), just proximal to the pulmonary valve.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium; Ao: aorta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16593=[""].join("\n");
var outline_f16_13_16593=null;
var title_f16_13_16594="Patient information: Genital warts (The Basics)";
var content_f16_13_16594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21906\">",
"         Patient information: Genital herpes (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/25/21907\">",
"         Patient information: HIV/AIDS (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/57/1940\">",
"         Patient information: Screening for sexually transmitted diseases (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/62/8162\">",
"         Patient information: Trichomoniasis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/3/36916\">",
"         Patient information: Genital herpes (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?3/60/4035\">",
"         Patient information: Genital warts in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/44/1730\">",
"         Patient information: Gonorrhea (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Genital warts (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/genital-warts-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H394373414\">",
"      <span class=\"h1\">",
"       What are genital warts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Genital warts are small, skin-colored or pink growths that form on the vulva (the lips of the vagina), vagina, penis, or anus. They are caused by a virus called human papillomavirus, or &ldquo;HPV.&rdquo; You can catch this virus during sex.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373421\">",
"      <span class=\"h1\">",
"       Is HPV dangerous?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The type of HPV that causes",
"      <strong>",
"      </strong>",
"      most forms of genital warts is not usually dangerous. But other types of HPV can lead to cancer of the cervix (a part inside the woman&rsquo;s body), penis, or anus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373428\">",
"      <span class=\"h1\">",
"       Do warts hurt or itch?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Not usually. Most people with genital warts have no symptoms (other than the warts). But some people have itching, burning, or tenderness.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373435\">",
"      <span class=\"h1\">",
"       Is there a test for genital warts?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No, there is no test. But your doctor or nurse should be able to tell if you have warts just by doing an exam. He or she might also take small samples of tissue (biopsy) if it is not clear what you have. But that is not usually necessary.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373442\">",
"      <span class=\"h1\">",
"       How are genital warts treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are several medicines that can help get rid of warts. Some work by slowly destroying the warts. Others work by getting your body&rsquo;s own infection-fighting system to attack the warts.",
"     </p>",
"     <p>",
"      Most medicines are lotions or gels that go on the warts. They have to be applied one or more times a week for many weeks. Some medicines must be applied by a doctor or nurse. Others you can apply yourself.",
"     </p>",
"     <p>",
"      People who do not get better with medicines or who have a very big wart or a lot of warts can have them removed. This is also an option for people who have warts that could become cancer.",
"     </p>",
"     <p>",
"      There are different treatments to remove warts:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cryotherapy, which uses a chemical to freeze warts",
"       </li>",
"       <li>",
"        Electrocautery, which uses electricity to burn away warts",
"       </li>",
"       <li>",
"        Traditional surgery, which involves cutting away warts",
"       </li>",
"       <li>",
"        Laser surgery, which uses light to destroy warts",
"       </li>",
"       <li>",
"        Ultrasound surgery, which uses sound waves to break up and remove warts (this is not available many places)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23450561\">",
"      <span class=\"h1\">",
"       What if I am pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, make sure to tell your doctor before you get treated for genital warts. Some of the treatments for genital warts are safe to use during pregnancy, but others are not. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373449\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After you have been treated for warts, your doctor or nurse may ask you to check once in a while to see if they come back. If warts are going to come back, they will probably do so within a few months.",
"     </p>",
"     <p>",
"      You should know that even if you cannot see any warts, you may still have HPV. That means that warts can come back at any time. If warts do come back, you could spread them to someone else.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373456\">",
"      <span class=\"h1\">",
"       Can genital warts be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are now vaccines against HPV. They can help prevent infection with most of the forms of HPV that cause warts. But the vaccines can prevent infection only if you get vaccinated before you get warts.",
"     </p>",
"     <p>",
"      You can also protect yourself by not having sex with anyone who is infected with HPV. But that is hard, because people do not always know that they have the virus. Condoms can help reduce the risk of infection. But they do not totally protect you. The virus can live on places on the skin not covered by a condom.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H394373463\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=see_link\">",
"       Patient information: Genital herpes (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=see_link\">",
"       Patient information: Screening for sexually transmitted diseases (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=see_link\">",
"       Patient information: HIV/AIDS (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=see_link\">",
"       Patient information: Trichomoniasis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=see_link\">",
"       Patient information: Genital warts in women (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"       Patient information: Gonorrhea (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=see_link\">",
"       Patient information: Genital herpes (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?16/13/16594?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15377 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16594=[""].join("\n");
var outline_f16_13_16594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373414\">",
"      What are genital warts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373421\">",
"      Is HPV dangerous?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373428\">",
"      Do warts hurt or itch?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373435\">",
"      Is there a test for genital warts?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373442\">",
"      How are genital warts treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23450561\">",
"      What if I am pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373449\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373456\">",
"      Can genital warts be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H394373463\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/3/36916?source=related_link\">",
"      Patient information: Genital herpes (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21906?source=related_link\">",
"      Patient information: Genital herpes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/60/4035?source=related_link\">",
"      Patient information: Genital warts in women (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=related_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/25/21907?source=related_link\">",
"      Patient information: HIV/AIDS (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1940?source=related_link\">",
"      Patient information: Screening for sexually transmitted diseases (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/62/8162?source=related_link\">",
"      Patient information: Trichomoniasis (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16595="Ciprofloxacin and dexamethasone: Drug information";
var content_f16_13_16595=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ciprofloxacin and dexamethasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/1/1044?source=see_link\">",
"    see \"Ciprofloxacin and dexamethasone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=see_link\">",
"    see \"Ciprofloxacin and dexamethasone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F854897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ciprodex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F151799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Otic;",
"     </li>",
"     <li>",
"      Antibiotic/Corticosteroid, Otic;",
"     </li>",
"     <li>",
"      Corticosteroid, Otic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F151784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute otitis externa: Otic: Instill 4 drops into affected ear(s) twice daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F151792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=see_link\">",
"      see \"Ciprofloxacin and dexamethasone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute otitis media in patients with tympanostomy tubes or acute otitis externa: Otic: Instill 4 drops into affected ear(s) twice daily for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F151785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15682658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F151770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, otic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ciprodex&reg;: Ciprofloxacin 0.3% and dexamethasone 0.1% (7.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F151760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F151772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Otic: Prior to instillation, bottle should be warmed in hands for 1-2 minutes. Shake suspension well immediately before using. Patient should lie with affected ear upward and remain in this position for 60 seconds following application. Drops should be instilled directly into tympanostomy tube (if present) and tragus should be pumped 5 times to facilitate penetration into the middle ear.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F151771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute otitis media in pediatric patients with tympanostomy tubes or acute otitis externa in children and adults",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F151797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Otic: Discomfort (3%), pain (&lt;1% to 2%), pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hearing decreased, ear congestion, ear erythema, ear residue, ear tingling, irritability, taste perversion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F151775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ciprofloxacin, other quinolones, dexamethasone, or any component of the formulation; not for use in viral infection of the external canal",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F151762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have been established in children &ge;6 months of age, however, the manufacturer states that there are no safety concerns which would preclude the use of this product in younger children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For otic use only; not intended for injection or ophthalmic use. Prior to instillation, suspension should be warmed in hands to prevent dizziness which may occur following use of a cold solution.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F151765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F151767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F151776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F151787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F151777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if serum levels of ciprofloxacin or dexamethasone are high enough following otic administration to produce detectable quantities in breast milk. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Ciprodex Otic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3-0.1% (7.5 mL): $173.22",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F854898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Cilodex (BR, CN, CO, IL, KP, MX, NZ, PE, PY, SG, UY);",
"     </li>",
"     <li>",
"      Ciloxadex (AR);",
"     </li>",
"     <li>",
"      Ciprodex (EC, PE, PY, UY);",
"     </li>",
"     <li>",
"      Ciproxxak (PE);",
"     </li>",
"     <li>",
"      Quinocort (VE);",
"     </li>",
"     <li>",
"      Sophixin DX Ofteno (CR, DO, GT, HN, NI, PA, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F151761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ciprofloxacin is a quinolone antibiotic; dexamethasone is a corticosteroid used to decrease inflammation accompanying bacterial infections",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F151774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Otic: Ciprofloxacin: Minor systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Otic: Ciprofloxacin: 15 minutes to 2 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9290 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16595=[""].join("\n");
var outline_f16_13_16595=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151783\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854897\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151799\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151784\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151792\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151785\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682658\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682659\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151770\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151760\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151772\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151771\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151797\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151775\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151762\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299047\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151765\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151767\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151776\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151787\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151777\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422207\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854898\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151761\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151774\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9290\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9290|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/1/1044?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/11/37042?source=related_link\">",
"      Ciprofloxacin and dexamethasone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16596="Ergoloid mesylates: Drug information";
var content_f16_13_16596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ergoloid mesylates: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/16/10500?source=see_link\">",
"    see \"Ergoloid mesylates: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hydergine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ergot Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Primary progressive dementia, Alzheimer's dementia: Oral: 1 mg 3 times/day up to 4.5-12 mg/day; up to 6 months of therapy may be necessary",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15822443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16355596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cerebrovascular insufficiency in primary progressive dementia, Alzheimer's dementia, and senile onset",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9961835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects are minimal; most common include transient nausea, gastrointestinal disturbances and sublingual irritation with SL tablets; other common side effects include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, orthostatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Flushing, skin rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ergot or any component of the formulation; acute or chronic psychosis; ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac valvular fibrosis: Ergot alkaloids have been associated with fibrotic valve thickening (eg, aortic, mitral, tricuspid); usually associated with long-term, chronic use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pleural/retroperitoneal fibrosis: Rare cases of pleural and/or retroperitoneal fibrosis have been reported with prolonged daily use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP3A4 inhibitors: Concomitant use with potent inhibitors of CYP3A4 (includes protease inhibitors, azole antifungals, and some macrolide antibiotics) and ergot alkaloids has been associated with acute ergot toxicity (ergotism); certain ergot alkaloids (eg, ergotamine and dihydroergotamine) are contraindicated by the manufacturer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use in this age group due to lack of efficacy (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lorcaserin: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically, use of these drugs together may increase the risk of developing valvular heart disease. Lorcaserin may enhance the serotonergic effect of Ergot Derivatives. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May enhance the adverse/toxic effect of Ergot Derivatives. Specifically leading to the development of ergotism.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: Ergot Derivatives may diminish the vasodilatory effect of Nitroglycerin. This is of particular concern in patients being treated for angina. Nitroglycerin may increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F166188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not eat or drink while tablet dissolves under tongue.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ergoloid Mesylates Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $810.41",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alergot (TH);",
"     </li>",
"     <li>",
"      Cirloid (ID);",
"     </li>",
"     <li>",
"      Ergomed (AT);",
"     </li>",
"     <li>",
"      Ergotika (ID);",
"     </li>",
"     <li>",
"      Ergotin (TW);",
"     </li>",
"     <li>",
"      Hodrin (TW);",
"     </li>",
"     <li>",
"      Hyceral (TH);",
"     </li>",
"     <li>",
"      Hydergin (AT, CH, FI, IL);",
"     </li>",
"     <li>",
"      Hydergina (CN, IT, MX, PE, UY, VE);",
"     </li>",
"     <li>",
"      Hydergine (AE, BE, BF, BH, BJ, BR, CI, CY, EG, ET, GH, GM, GN, GR, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, OM, PH, QA, SA, SC, SD, SE, SL, SN, SY, TH, TN, TW, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Procere (ID);",
"     </li>",
"     <li>",
"      Redergam (HN);",
"     </li>",
"     <li>",
"      Redergin (HR);",
"     </li>",
"     <li>",
"      Secatoxin Forte (CZ);",
"     </li>",
"     <li>",
"      Togine (TH);",
"     </li>",
"     <li>",
"      Trigogine (SG);",
"     </li>",
"     <li>",
"      Vasian (TH);",
"     </li>",
"     <li>",
"      Vasobral (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ergoloid mesylates do not have the vasoconstrictor effects of the natural ergot alkaloids; exact mechanism in dementia is unknown; originally classed as peripheral and cerebral vasodilator, now considered a &ldquo;metabolic enhancer&rdquo;; there is no specific evidence which clearly establishes the mechanism by which ergoloid mesylate preparations produce mental effects, nor is there conclusive evidence that the drug particularly affects cerebral arteriosclerosis or cerebrovascular insufficiency",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid yet incomplete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination, serum: 3.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: &sim;1 hour",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16596/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9414 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-AA34A315B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16596=[""].join("\n");
var outline_f16_13_16596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166194\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166206\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166197\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166198\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822443\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822444\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166182\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166169\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16355596\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166183\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9961835\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166204\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166173\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166203\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166177\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166188\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166187\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166189\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166172\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/16/10500?source=related_link\">",
"      Ergoloid mesylates: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16597="Interferon beta-1b: Drug information";
var content_f16_13_16597=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Interferon beta-1b: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/29/8661?source=see_link\">",
"    see \"Interferon beta-1b: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Betaseron&reg;;",
"     </li>",
"     <li>",
"      Extavia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Betaseron&reg;;",
"     </li>",
"     <li>",
"      Extavia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F183563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F183548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Gradual dose-titration, analgesics, and/or antipyretics may help decrease flu-like symptoms on treatment days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (relapsing):",
"     </b>",
"     Initial: 0.0625 mg (2 million units [0.25 mL]) every other day; gradually increase dose by 0.0625 every 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Target dose:",
"     </i>",
"     0.25 mg (8 million units [1 mL]) every other day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis (secondary-progressive) [Canadian labeling; not in U.S. labeling]:",
"     </b>",
"     Initial: 0.125 mg (4 million units [0.5 mL]) every other day for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Target dose:",
"     </i>",
"     0.25 mg (8 million units [1 mL]) every other day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F183557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended in children &lt;18 years of age",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F183549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15897902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Betaseron&reg;: 0.3 mg [~9.6 million units] [contains albumin (human); supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extavia&reg;: 0.3 mg [~9.6 million units] [contains albumin (human); supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Betaseron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088565.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088565.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Extavia&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180718.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM180718.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F183528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdraw dose of reconstituted solution from the vial into a sterile syringe fitted with a 27-gauge needle and inject the solution subcutaneously; sites for self-injection include outer surface of the arms, abdomen, hips, and thighs. Rotate SubQ injection site. Patient should be well hydrated.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F183527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of relapsing forms of multiple sclerosis (MS); treatment of first clinical episode with MRI features consistent with MS",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Treatment of secondary-progressive MS",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F183561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Flu-like syndrome (including at least two of the following - headache, fever, chills, malaise, diaphoresis, and myalgia) are reported in the majority of patients (60%) and decrease over time (average duration ~1 week).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (15%), chest pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (57%), fever (36%), pain (51%), chills (25%), dizziness (24%), insomnia (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (24%), skin disorder (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Metrorrhagia (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (27%), diarrhea (19%), abdominal pain (19%), constipation (20%), dyspepsia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary urgency (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphopenia (88%), neutropenia (14%), leukopenia (14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (85%), inflammation (53%), pain (18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (61%), myalgia (27%), hypertonia (50%), myasthenia (46%), arthralgia (31%), incoordination (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (decreases over treatment course; 60%), neutralizing antibodies (&le;45%; significance not known)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Palpitation (4%), vasodilation (8%), hypertension (7%), tachycardia (4%), peripheral vascular disorder (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety (10%), malaise (8%), nervousness (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menorrhagia (8%), dysmenorrhea (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence (9%), pelvic pain (6%), cystitis (8%), urinary frequency (7%), prostatic disorder (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphadenopathy (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT increased &gt;5x baseline (10%), AST increased &gt;5x baseline (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site necrosis (4% to 5%), edema (3%), mass (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Leg cramps (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (8%), hypersensitivity (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anorexia, apnea, arrhythmia, ataxia, autoimmune hepatitis, bronchospasm, capillary leak syndrome (in patients with pre-existing monoclonal gammopathy) , cardiac arrest, cardiomegaly, cardiomyopathy, cerebral hemorrhage, coma, confusion, delirium, depersonalization, depression, DVT, emotional lability, erythema nodosum, ethanol intolerance, exfoliative dermatitis, gamma GT increase, GI hemorrhage, hallucinations, heart failure, hematemesis, hepatic failure, hepatitis, hyperthyroidism, hyperuricemia, hypocalcemia, mania, MI, pancreatitis, paresthesia, pericardial effusion, photosensitivity, pneumonia, pruritus, psychosis, pulmonary embolism, rash, seizure, sepsis, shock, skin discoloration, suicidal ideation, syncope, SIADH, thrombocytopenia, thyroid dysfunction, triglyceride increased, urinary tract infection, urosepsis, urticaria, vasculitis, vaginal hemorrhage, vomiting, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F183531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to",
"     <i>",
"      E. coli",
"     </i>",
"     -derived products, natural or recombinant interferon beta, albumin human or any other component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindication (not in U.S. labeling): Pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F183515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis: Has been reported rarely with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Associated with a high incidence of flu-like adverse effects; use of analgesics and/or antipyretics on treatment days may be helpful. Improvement in symptoms occurs over time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity: Has been reported with beta interferons, including rare reports of hepatitis (autoimmune) and hepatic failure requiring transplant; use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyper-/hypothyroidism: Thyroid dysfunction has rarely been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infection: Increased risk of infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection site reactions: Severe injection site reactions (necrosis) may occur, which may or may not heal with continued therapy; patient and/or caregiver competency in injection technique should be confirmed and periodically re-evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Leukopenia: Routine monitoring is recommended; dose reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders: Interferons have been associated with severe psychiatric adverse events (psychosis, mania, depression, suicidal behavior/ideation) in patients with and without previous psychiatric symptoms, avoid use in severe psychiatric disorders and use caution in patients with a history of depression; patients exhibiting symptoms of depression should be closely monitored and discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Use with caution in patients with bone marrow suppression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease, including angina, HF, and/or arrythmia. Rare cases of new-onset cardiomyopathy and/or HF have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Contains albumin, which may carry a remote risk of transmitting Creutzfeldt-Jakob or other viral diseases.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F183522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F183535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A dose-related abortifacient activity was reported in Rhesus monkeys. There are no adequate and well-controlled studies in pregnant women. Treatment should be discontinued if a woman becomes pregnant, or plans to become pregnant during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F183552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F183536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because its use has not been evaluated during lactation, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F183534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Betaseron Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (1): $350.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Extavia Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.3 mg (1): $305.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F183524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Complete blood chemistries (including platelet count) and liver function tests are recommended at 1, 3, and 6 months following initiation of therapy and periodically thereafter. Thyroid function should be assessed every 6 months in patients with history of thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional monitoring recommendations (not in U.S. labeling): Baseline pregnancy test, chest X-ray, and ECG",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F183537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Betaferon (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, UY, ZA);",
"     </li>",
"     <li>",
"      Extavia (BE, CZ, DK, EE, FR, GB, GR, IE, IT, NL, NO, PL, PT, SE);",
"     </li>",
"     <li>",
"      Uribeta (CR, DO, GT, HN, PA, SV)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F183514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferon beta-1b differs from naturally occurring human protein by a single amino acid substitution and the lack of carbohydrate side chains; mechanism in the treatment of MS is unknown; however, immunomodulatory effects attributed to interferon beta-1b include enhancement of suppressor T cell activity, reduction of proinflammatory cytokines, down-regulation of antigen presentation, and reduced trafficking of lymphocytes into the central nervous system. Improves MRI lesions, decreases relapse rate, and disease severity in patients with secondary progressive MS.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F183530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limited data due to small doses used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 8 minutes to 4.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-8 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goodin DS, Frohman EM, Garmany GP, et al, &ldquo;Disease Modifying Therapies In Multiple Sclerosis: Report Of The Therapeutics And Technology Assessment Subcommittee Of The American Academy Of Neurology And The MS Council For Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 2002, 58:169-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16597/abstract-text/11805241 /pubmed\" id=\"11805241 \" target=\"_blank\">",
"        11805241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sheremata WA, Taylor JR, and Elgart GW, &ldquo;Severe Necrotizing Cutaneous Lesions Complicating Treatment With Interferon Beta-1b,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(23):1584.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16597/abstract-text/7739724/pubmed\" id=\"7739724\" target=\"_blank\">",
"        7739724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8566 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16597=[""].join("\n");
var outline_f16_13_16597=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183545\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183546\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183563\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183548\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183557\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183549\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897901\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897902\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183526\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183511\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874832\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183528\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183527\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183561\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183531\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183515\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299524\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183520\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183522\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183535\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183552\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183536\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183534\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183524\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183537\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183514\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183530\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8566\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8566|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/29/8661?source=related_link\">",
"      Interferon beta-1b: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16598="Rates of gonorrhea by state";
var content_f16_13_16598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Gonorrhea rates in the united states - 2000",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Division of STD Prevention. Sexually Transmitted Disease Surveillance, 2000. U.S. Department of Health and Human Services, Public Health Service. Atlanta: Centers for Disease Control and Prevention (CDC), September, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16598=[""].join("\n");
var outline_f16_13_16598=null;
var title_f16_13_16599="Sumatriptan: Pediatric drug information";
var content_f16_13_16599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sumatriptan: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"    see \"Sumatriptan: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15958?source=see_link\">",
"    see \"Sumatriptan: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F224276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alsuma&trade;;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Sumavel&reg; DosePro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F224277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sumatriptan&reg;;",
"     </li>",
"     <li>",
"      Ava-Sumatriptan;",
"     </li>",
"     <li>",
"      CO Sumatriptan;",
"     </li>",
"     <li>",
"      Dom-Sumatriptan;",
"     </li>",
"     <li>",
"      Imitrex&reg;;",
"     </li>",
"     <li>",
"      Imitrex&reg; DF;",
"     </li>",
"     <li>",
"      Imitrex&reg; Injection;",
"     </li>",
"     <li>",
"      Imitrex&reg; Nasal Spray;",
"     </li>",
"     <li>",
"      Mylan-Sumatriptan;",
"     </li>",
"     <li>",
"      PHL-Sumatriptan;",
"     </li>",
"     <li>",
"      PMS-Sumatriptan;",
"     </li>",
"     <li>",
"      Riva-Sumatriptan;",
"     </li>",
"     <li>",
"      Sandoz-Sumatriptan;",
"     </li>",
"     <li>",
"      Sumatriptan Injection;",
"     </li>",
"     <li>",
"      Sumatriptan Sun Injection;",
"     </li>",
"     <li>",
"      Sumatryx;",
"     </li>",
"     <li>",
"      Taro-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan;",
"     </li>",
"     <li>",
"      Teva-Sumatriptan DF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antimigraine Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1055578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=see_link\">",
"      see \"Sumatriptan: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Use in children and adolescents &lt;18 years of age not recommended by manufacturer. Results of clinical studies are mixed with regards to efficacy, particularly with oral and injectable sumatriptan; a 2004 practice parameter concluded that sumatriptan nasal spray was effective for the acute treatment of migraines in adolescent patients (Lewis, 2004); additional studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-12 years: 5 mg, 10  mg, or 20 mg administered in one nostril",
"     <b>",
"      as a single dose",
"     </b>",
"     , given as soon as possible after the onset of migraine; dose should be selected on an individual basis; optimal dose not established. A double-blind, placebo controlled study of 129 patients (8-17 years; mean 12.4 years) used a weight-based dosing regimen: Body weight: 20-39 kg: 10 mg/dose; body weight &ge;40 kg: 20 mg/dose; however, relatively few children &lt;12 years old were included in the study (Ahonen, 2004). A small, randomized, double-blind, placebo-controlled study of 14 children (6-9 years; median: 8.2 years) used intranasal doses of 20 mg/dose (Ueberall, 1999). A small, retrospective review of 10 children (5-12 years; mean: 9.9 years), used intranasal doses of 5 mg (n=2) or 20 mg (n=8) (Hershey, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;12 years: 5 mg, 10 mg, or 20 mg administered in one nostril",
"     <b>",
"      as a single dose",
"     </b>",
"     given as soon as possible after the onset of migraine; dose should be selected on an individual basis (Lewis, 2004; Rothner, 2000; Winner, 2000; Winner, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial single dose: 5 mg, 10 mg, or 20 mg administered in one nostril, given as soon as possible after the onset of migraine; dose should be selected on an individual basis; 10 mg dose may be administered as 5 mg in each nostril; may repeat after 2 hours; maximum: 40 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents 6-18 years: 3-6 mg single dose. An open-labeled prospective trial of 17 children 6-16 years with juvenile migraine used SubQ doses of 6 mg in 15 children (30-70 kg), and 3 mg/dose in two children (22 kg and 30 kg) (MacDonald, 1994). Another open-label prospective trial in 50 consecutive children (ages 6-18 years) with severe migraine used SubQ doses of 0.06 mg/kg/dose. Relief was reported as good/excellent in 84% of the patients; 16% reported fair to poor relief; additional studies are needed (Linder, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial: 4-6 mg; may repeat if needed &ge;1 hour after initial dose; maximum: 12 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents: Efficacy of oral sumatriptan was",
"     <b>",
"      not",
"     </b>",
"     established in five controlled trials in adolescent patients; frequency of adverse events was dose-related and age-dependent (ie, younger patients reported more adverse events)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Initial single dose: 25 mg given as soon as possible after the onset of a migraine; range: 25-100 mg/dose; dose should be selected on an individual basis; maximum single dose: 100 mg; may repeat after 2 hours; maximum: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild to moderate hepatic impairment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intranasal: Has not been studied in patients with hepatic impairment; however, because the intranasally administered drug does not undergo first-pass metabolism, serum concentrations would not be expected to be altered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ: Has been studied and pharmacokinetics were not altered in patients with hepatic impairment compared to healthy patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe hepatic impairment: Oral, nasal, and SubQ (limited to Imitrex&reg; injection, per prescribing information) formulations are contraindicated with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustments are recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F224252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as succinate [strength expressed as base]: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alsuma&trade;: 6 mg/0.5 mL (0.5 mL) [autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL) [cartridge]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 6 mg/0.5 mL (0.5 mL) [vial]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sumavel&reg; DosePro&reg;: 6 mg/0.5 mL (0.5 mL) [needleless autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as succinate [strength expressed as base, preservative free]: 6 mg/0.5 mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal [spray]: 5 mg/0.1 mL (6s); 20 mg/0.1 mL (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 5 mg/0.1 mL (6s); 20 mg/0.1 mL (6s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as succinate [strength expressed as base]: 25 mg, 50 mg, 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imitrex&reg;: 25 mg, 50 mg, 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F224238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16031498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Zecuity&trade; (transdermal system): FDA approved January 2013; availability anticipated in fourth quarter of 2013.  Refer to prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Each nasal spray unit is preloaded with 1 dose;",
"     <b>",
"      do not",
"     </b>",
"     test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10-20 seconds and gently breathe in through nose and out through mouth;",
"     <b>",
"      do not breathe deeply",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with water or other fluids; swallow tablet whole; do not split tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: SubQ use only; do",
"     <b>",
"      not",
"     </b>",
"     administer I.M.; do",
"     <b>",
"      not",
"     </b>",
"     administer I.V. (may cause coronary vasospasm). Needle penetrates",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     inch of skin; use in areas of the body with adequate skin and subcutaneous thickness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alsuma&trade; is a prefilled single use autoinjector device; product information suggests SubQ administration into lateral thigh or upper arm (adults). Discard after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Needleless administration (Sumavel&reg; DosePro&reg;): Do",
"     <b>",
"      not",
"     </b>",
"     administer I.M.; do",
"     <b>",
"      not",
"     </b>",
"     administer I.V. (may cause coronary vasospasm). Administer SubQ to the abdomen (&gt;2 inches from the navel) or thigh; do not administer to other areas of the body (eg, arm). Sumavel&reg; DosePro&reg; device is for single use only; discard after use; do not use if the tip of the device is tilted or broken;",
"     <b>",
"      Note:",
"     </b>",
"     A loud burst of air will be heard and a sensation in the skin will be felt at the time a dose is delivered with this device .",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1055581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alsuma&trade;: Store at 25&deg;C (77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F to 86&deg;F); do not refrigerate; protect from light. Store each autoinjector in its storage and disposal case; remove from case only prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection (Imitrex&reg;), nasal spray, tablets: Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F); protect from light",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sumavel&reg; DosePro&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted between 15&deg;C and 30&deg;C (59&deg;F to 86&deg;F); do not freeze",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, intranasal, and tablets: Acute treatment of migraine with or without aura (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Acute treatment of cluster headaches (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F224330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       SUMAtriptan may be confused with saxagliptin, sitaGLIPtin, somatropin, ZOLMitriptan",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F224328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest discomfort/tightness/pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, burning sensation, cold sensation, dizziness, drowsiness, fatigue, feeling of heaviness, feeling of tightness, feeling strange, flushing, headache, malaise, pressure sensation, headache, tight feeling in head, warm/hot sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, dysphagia, nausea/vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (includes bleeding, bruising, edema, and erythema)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Jaw discomfort, muscle cramps, myalgia, neck pain/stiffness, numbness, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Vision alterations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchospasm, nasal disorder/discomfort, throat discomfort",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nasal spray:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Bad taste, nasal disorder/discomfort, nausea, throat discomfort, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain/tightness/heaviness/pressure, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Burning, dizziness, drowsiness, fatigue, headache, malaise, migraine, nonspecified pain, sleepiness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, hyposalivation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hemolytic anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia; neck, throat, and jaw pain/tightness/pressure;  numbness, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear hemorrhage, hearing loss, sensitivity to noise, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Allergic rhinitis, dyspnea, nasal inflammation, nose/throat hemorrhage, sinusitis, upper respiratory inflammation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity reactions, nonspecified pressure/tightness/heaviness, warm/cold sensation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Route unspecified:",
"     </b>",
"     Postmarketing and uncontrolled studies (limited to important or life-threatening): Abdominal aortic aneurysm, abnormal/elevated liver function tests, accommodation disorders, acute renal failure, anaphylactoid reaction, anaphylaxis, anemia, angioneurotic edema, arrhythmia, atrial fibrillation, bronchospasm, cardiomyopathy, cerebral ischemia, cerebrovascular accident, colonic ischemia, coronary artery vasospasm, cyanosis, deafness, ECG changes, hallucinations, heart block, hematuria, hemolytic anemia, hypersensitivity reactions, hyper-/hypotension, hypertensive crises, intestinal obstruction, intracranial pressure increased, ischemic colitis, MI, nose/throat hemorrhage, optic neuropathy (ischemic), pancytopenia, paresthesia, phlebitis, photosensitivity, Prinzmetal's angina, pulmonary embolism, Raynaud syndrome, retinal artery occlusion, retinal vein thrombosis, seizures, serotonin syndrome, shock, subarachnoid hemorrhage, syncope, temporal arteritis, thrombocytopenia, thrombophlebitis, thrombosis, transaminases increased, transient myocardial ischemia, TSH increased, vasculitis, ventricular fibrillation, ventricular tachycardia, vision loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sumatriptan or any component; I.V. administration (coronary vasospasm may occur); patients with ischemic heart disease or signs or symptoms of ischemic heart disease (eg, angina pectoris, Prinzmetal angina, MI, silent MI); other significant underlying cardiovascular diseases); cerebrovascular syndromes (eg, stroke, TIA); peripheral vascular diseases (eg, ischemic bowel disease), severe hepatic impairment (oral and nasal sumatriptan, and injectable Imitrex&reg; only); uncontrolled hypertension; concomitant use (within last 24 hours) of ergotamine, ergotamine derivatives (eg, dihydroergotamine, methysergide), other 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonists (triptans), or MAO inhibitors; use of MAO inhibitors within past 2 weeks (oral and nasal sumatriptan formulations only); management of hemiplegic or basilar migraine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1055577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with controlled hypertension; temporary increases in peripheral vascular resistance and blood pressure may occur; significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension; use is contraindicated in patients with uncontrolled hypertension. Use oral formulations of sumatriptan with caution and in reduced doses in patients with impaired hepatic function; presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations. Nonoral routes of administration (nasal, subcutaneous formulations) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, nasal, or Imitrex&reg; injectable dosage form is contraindicated in severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Use with caution in patients with a history of seizure disorder or conditions associated with a decrease in the seizure threshold. Although generally not recommended, if concomitant use of an MAO inhibitor with injectable sumatriptan is deemed necessary, careful monitoring and appropriate dosage adjustments are required (",
"     <b>",
"      Note:",
"     </b>",
"     Use of MAO inhibitors within past 2 weeks is contraindicated with oral and nasal sumatriptan). Other potentially serious neurological conditions should be ruled out prior to acute migraine therapy. Sumatriptan (given at 5 times the maximum oral single dose) has caused corneal opacities in dogs; other animal studies suggest it may bind to the melanin of the eye; human studies are not available",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Serious adverse effects, such as MI, stroke, visual loss, and death have been reported in pediatric patients after sumatriptan use by the oral, intranasal, and/or SubQ route; frequency of such adverse effects cannot currently be determined, thus the use of sumatriptan in patients &lt;18 years of age is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1055576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Life-threatening or fatal hypersensitivity reactions may occur. Rarely, serious coronary events, including coronary artery vasospasm, transient ischemia, acute MI, life-threatening arrhythmias, cardiac arrest, and death, may occur; avoid use in patients with risk factors for coronary artery disease, unless cardiovascular disease can be ruled out; consider administering first dose under close supervision to patients at high risk for coronary disease; ECG should be performed if angina-like symptoms occur; periodically evaluate cardiovascular system in patients with risk factors for coronary artery disease. Cerebrovascular events (eg, cerebral hemorrhage, subarachnoid hemorrhage, stroke) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonist (triptan) administration. Vasospasm-related events (eg, peripheral vascular ischemia, colonic ischemia) have been reported with 5-HT",
"     <sub>",
"      1",
"     </sub>",
"     agonists. Transient and permanent blindness and significant partial vision loss have been very rarely reported. Potentially fatal serotonin syndrome may occur when triptans are used in combination with SSRIs (eg, fluoxetine, sertraline) or SNRIs (eg, venlafaxine); monitor carefully if the two drugs are used concomitantly.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F224247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablets: A high-fat meal increases peak concentrations by 15% and AUC by 12% compared to the fasting state.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F224249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F224262\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using sumatriptan in pregnant women. Use only if potential benefit to the mother outweighs the potential risk to the fetus. A pregnancy registry has been established to monitor outcomes of women exposed to sumatriptan during pregnancy (800-336-2176). Preliminary data from the registry do not suggest a greater risk of birth defects than the general population and so far a specific pattern of malformations has not been identified. However, sample sizes are small and studies are ongoing. In some (but not all) animal studies, administration was associated with embryolethality, fetal malformations and pup mortality.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1055575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selective agonist for serotonin (5-HT",
"     <sub>",
"      1",
"     </sub>",
"     ) receptor in cranial arteries; causes vasoconstriction and reduces sterile inflammation associated with antidromic neuronal transmission correlating with relief of migraine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Migraine pain relief:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nasal: ~15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 10 minutes to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Oral: 2-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes to breast milk following SubQ administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (central): 50 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): 2.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 14% to 21%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to an indole acetic acid metabolite (inactive) which then undergoes ester glucuronide conjugation; may be metabolized by monoamine oxidase (MAO); extensive first-pass metabolism following oral administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: &sim;15%; may be significantly increased with liver disease",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal: 17% (compared to SubQ)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 97%;",
"     <b>",
"      Note:",
"     </b>",
"     Sumavel&reg; DosePro&reg; is bioequivalent to sumatriptan SubQ injection via needle when administered into the thigh or abdomen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Distribution: 15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Terminal: 2 hours; range: 1-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Healthy adults: 2 hours; during migraine attacks: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: Range: 5-20 minutes; mean: 12 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 60% of an oral dose is renally excreted (primarily as metabolites), 40% is eliminated via the feces, and only 3% as unchanged drug; 42% of an intranasal dose is excreted as the indole acetic acid metabolite with 3% excreted in the urine unchanged; 22% of a SubQ dose is excreted in urine unchanged and 38% as the indole acetic acid metabolite",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15958?source=see_link\">",
"      see \"Sumatriptan: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If pain or tightness in chest or throat occurs, notify physician. Females should avoid pregnancy. Pain at injection site lasts &lt;1 hour. Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F12591646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The safety of treating an average of &gt;4 headaches in a 30-day period has not been established. Sumatriptan is",
"     <b>",
"      not",
"     </b>",
"     indicated for migraine prophylaxis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Sumavel&reg; DosePro&reg; is a single-use, prefilled, disposable, needle-free SubQ delivery system; it uses pressure from a compressed nitrogen gas source to deliver medication via a small, precise hole in the glass medication chamber; medication is propelled through the skin and delivered SubQ without a needle.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F11450256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 5 mg/mL oral liquid preparation made from tablets and one of three different vehicles (Ora-Sweet&reg;, Ora-Sweet&reg; SF, or Syrpalta&reg; syrups).",
"     <b>",
"      Note:",
"     </b>",
"     Ora-Plus&reg; Suspending Vehicle is used with Ora-Sweet&reg; or Ora-Sweet&reg; SF to facilitate dispersion of the tablets (Ora-Plus&reg; is not necessary if Syrpalta&reg; is the vehicle). Crush nine 100 mg tablets in a mortar and reduce to a fine powder. Add 40 mL of Ora-Plus&reg; in 5 mL increments and mix thoroughly between each addition; rinse mortar and pestle 5 times with 10 mL of Ora-Plus&reg;, pouring into bottle each time, and add quantity of appropriate syrup (Ora-Sweet&reg; or Ora-Sweet&reg; SF) sufficient to make 180 mL. Store in amber glass bottles in the dark; label \"shake well\", \"refrigerate\", and \"protect from light\". Stable for 21 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Fish DN, Beall HD, Goodwin SD, et al, \"Stability of Sumatriptan Succinate in Extemporaneously Prepared Oral Liquids,\"",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1997, 54(14):1619-22.",
"     <span class=\"pubmed-id\">",
"      9248606",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahonen K, H&auml;m&auml;l&auml;inen ML, Rantala H, et al, \"Nasal Sumatriptan Is Effective in Treatment of Migraine Attacks in Children: A Randomized Trial,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 62(6):883-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/15037686/pubmed\" id=\"15037686\" target=\"_blank\">",
"        15037686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gunner KB, Smith HD, and Ferguson LE, \"Practice Guideline for Diagnosis and Management of Migraine Headaches in Children and Adolescents: Part Two,\"",
"      <i>",
"       J Pediatr Health Care",
"      </i>",
"      , 2008, 22(1):52-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/18174091/pubmed\" id=\"18174091\" target=\"_blank\">",
"        18174091",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hershey AD, Powers SW, LeCates S, et al, &ldquo;Effectiveness of Nasal Sumatriptan in 5- to 12-Year-Old Children,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 2001, 41(7):693-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/11554957 /pubmed\" id=\"11554957 \" target=\"_blank\">",
"        11554957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lewis D, Ashwal S, Hershey A, et al, \"Practice Parameter: Pharmacological Treatment of Migraine Headache in Children and Adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2004, 63(12):2215-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/15623677/pubmed\" id=\"15623677\" target=\"_blank\">",
"        15623677",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Linder SL, \"Subcutaneous Sumatriptan in the Clinical Setting: The First 50 Consecutive Patients With Acute Migraine in a Pediatric Neurology Office Practice,\"",
"      <i>",
"       Headache",
"      </i>",
"      , 1996, 36(7):419-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/8783473/pubmed\" id=\"8783473\" target=\"_blank\">",
"        8783473",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      MacDonald JT, &ldquo;Treatment of Juvenile Migraine With Subcutaneous Sumatriptan,&rdquo;",
"      <i>",
"       Headache",
"      </i>",
"      , 1994, 34(10):581-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/7843952 /pubmed\" id=\"7843952 \" target=\"_blank\">",
"        7843952",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothner AD, Winner P, Nett R, et al, \"One-Year Tolerability and Efficacy of Sumatriptan Nasal Spray in Adolescents With Migraine: Results of a Multicenter, Open-Label Study,\"",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2000, 22(12):1533-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/11192144/pubmed\" id=\"11192144\" target=\"_blank\">",
"        11192144",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott AK, &ldquo;Sumatriptan Clinical Pharmacokinetics,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(5):337-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/ 7851052 /pubmed\" id=\" 7851052 \" target=\"_blank\">",
"        7851052",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silver S, Gano D, and Gerretsen P, \"Acute Treatment of Paediatric Migraine: A Meta-analysis of Efficacy,\"",
"      <i>",
"       J Paediatr Child Health",
"      </i>",
"      , 2008, 44(1-2):3-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/17854415/pubmed\" id=\"17854415\" target=\"_blank\">",
"        17854415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ueberall MA and Wenzel D, \"Intranasal Sumatriptan for the Acute Treatment of Migraine in Children,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 1999, 52(7):1507-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/10227648/pubmed\" id=\"10227648\" target=\"_blank\">",
"        10227648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winner P, Rothner AD, Saper J, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(5):989-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/13/16599/abstract-text/11061765/pubmed\" id=\"11061765\" target=\"_blank\">",
"        11061765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winner P, Rothner AD, Wooten JD, et al, \"Sumatriptan Nasal Spray in Adolescent Migraineurs: A Randomized, Double-Blind, Placebo-Controlled, Acute Study,\"",
"      <i>",
"       Headache",
"      </i>",
"      , 2006, 46(2):212-22.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12821 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.15-89E53B5A98-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16599=[""].join("\n");
var outline_f16_13_16599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055584\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055578\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224252\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224238\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16031498\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055588\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055581\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055587\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224330\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224328\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055593\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055577\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055576\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300101\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224247\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055596\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224249\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F224262\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055575\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055591\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055592\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055583\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12591646\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11450256\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/38/5736?source=related_link\">",
"      Sumatriptan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/37/15958?source=related_link\">",
"      Sumatriptan: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16600="Epidemiology and clinical features of gram-negative bacillary meningitis";
var content_f16_13_16600=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology and clinical features of gram-negative bacillary meningitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16600/contributors\">",
"     N Deborah Friedman, MPH, MBBS, FRACP, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16600/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/13/16600/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of gram-negative bacillary meningitis occur in neonates or infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/1\">",
"     1",
"    </a>",
"    ]. Gram-negative bacilli are the fifth most common cause of meningitis in infants, accounting for 3.6 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. By contrast, gram-negative bacilli are an uncommon etiology of community-acquired meningitis in adults, but are a common cause of nosocomial meningitis, often occurring as a complication of head trauma and craniotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology and clinical features of gram-negative bacillary meningitis will be reviewed here. Issues related to diagnosis and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=see_link\">",
"     \"Diagnosis and treatment of gram-negative bacillary meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative meningitis was first recognized and reported in 1892. In the 1930s and 40s, cases were described resulting from abortion, genitourinary manipulation, and spinal anesthesia. In the following two decades, gram-negative bacillary meningitis was recognized as an occasional complication of injuries and neurosurgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, gram-negative bacillary meningitis has become an important cause of hospital-associated central nervous system (CNS) infection in adults, usually due to neurosurgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/5\">",
"     5",
"    </a>",
"    ]. The likelihood of post-neurosurgery meningitis being due to gram-negative organisms is increased when antimicrobial prophylaxis, which predominantly provides gram-positive coverage, is given to prevent surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Nosocomial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Neurosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the incidence of gram-negative bacillary meningitis has increased as progressively more complex neurosurgical techniques and operations become more commonplace, this is still a rare infection. As an example, meningitis caused by Enterobacteriaceae accounted for 1.5 percent of all cases of acute bacterial meningitis in adults over a 20 year period in one Danish hospital [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition, of 1961 isolates of gram-negative bacilli from blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cerebrospinal fluid (CSF) specimens over a two year period at our institution, only 47 (2.4 percent) were from the CSF (unpublished data).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major pathogenetic distinction in the development of meningitis due to gram-negative bacilli compared with organisms that more commonly produce meningitis, such as Streptococcus pneumoniae, is in the route of penetration into the CSF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\", section on 'Meningeal invasion'",
"    </a>",
"    .) The CSF is normally deficient in immunoglobulins and complement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/8\">",
"     8",
"    </a>",
"    ]. If bacterial contamination of the CSF occurs secondary to trauma, surgery or bacteremic seeding, there is an impairment in the ability of the CSF to effectively opsonize and phagocytose microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The development of bacterial meningitis progresses through four interconnected phases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacterial invasion of the host with subsequent infection of the CNS",
"     </li>",
"     <li>",
"      Bacterial multiplication and induction of inflammation in the subarachnoid and ventricular space",
"     </li>",
"     <li>",
"      Progression of inflammation with associated pathophysiologic alterations",
"     </li>",
"     <li>",
"      Development of neuronal damage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bacteria usually reach the CSF by bloodstream invasion, which follows nasopharyngeal colonization for organisms such as Neisseria meningitidis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=see_link\">",
"     \"Epidemiology of Neisseria meningitidis infection\"",
"    </a>",
"    .) Nonhematogenous invasion of the CSF by bacteria occurs in situations of compromised integrity of the barriers surrounding the brain, such as neurosurgery, trauma, otitis media, mastoiditis, sinusitis and malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three patterns of meningitis caused by gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ]: neonatal meningitis, meningitis, usually nosocomial, secondary to trauma or neurosurgery, and spontaneous gram-negative meningitis in adults. Among adults, approximately 60 percent of cases are spontaneous [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,11\">",
"     4,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Neonatal meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates and infants, gram-negative bacillary meningitis is usually associated with neural tube defects and urinary tract anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. The majority of neonates with E. coli meningitis are infected with strains of E. coli that have the K1 capsular polysaccharide [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/12\">",
"     12",
"    </a>",
"    ]. This bacterial capsule like those of S. pneumoniae, N. meningitidis, and Haemophilus influenzae can assist the organism in evading host defenses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link\">",
"     \"Epidemiology of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=see_link\">",
"     \"Microbiology and pathobiology of Neisseria meningitidis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neonatal E. coli meningitis typically occurs soon after birth, and epidemiologic data suggest that such infections are usually acquired during or soon after delivery. The source of these organisms may be the vaginal flora of the mother or the hands of hospital personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=see_link\">",
"     \"Clinical features and diagnosis of bacterial meningitis in the neonate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Nosocomial meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of 493 episodes of bacterial meningitis in adults seen in the Boston area between 1962 and 1988, gram-negative organisms accounted for 33 percent of nosocomial infections compared to only 3 percent of community-acquired infections [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/14\">",
"     14",
"    </a>",
"    ]. The major risk factors for nosocomial meningitis were neurosurgery or head trauma within the past month, a neurosurgical device, and a CSF leak, which accounted for 75 percent of cases.",
"   </p>",
"   <p>",
"    Anything that causes disruption of the dura mater, such as neurosurgery or trauma, can predispose to meningeal infection. In several series 36 to 50 percent of cases of gram-negative bacillary meningitis occurred after neurosurgical procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,11,14,15\">",
"     4,11,14,15",
"    </a>",
"    ]. Although many such cases are due to gram-positive organisms, particularly Staphylococci, gram-negative bacilli account for an important percentage. The likelihood of post-neurosurgery meningitis being due to gram-negative organisms is increased when antimicrobial prophylaxis, which predominantly provides gram-positive coverage, is given to prevent surgical site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of bacterial meningitis in adults\", section on 'Nosocomial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Neurosurgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurosurgical procedures most likely to be complicated by gram-negative infection include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventriculoperitoneal shunt insertion",
"     </li>",
"     <li>",
"      Ventriculostomy",
"     </li>",
"     <li>",
"      Repair of CSF fistula",
"     </li>",
"     <li>",
"      Ommaya or Rickham reservoir insertion",
"     </li>",
"     <li>",
"      Craniofacial resection",
"     </li>",
"     <li>",
"      Hypophysectomy",
"     </li>",
"     <li>",
"      Myelography",
"     </li>",
"     <li>",
"      Transsphenoidal surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One review of meningitis complicating ventriculoperitoneal shunt insertion in children, found the incidence of meningitis to be 6.3 percent per insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/16\">",
"     16",
"    </a>",
"    ]. The major responsible organisms in this series were coagulase-negative staphylococci (53 percent), Staphylococcus aureus (13 percent), and P. aeruginosa (8 percent). Rates of meningitis following transsphenoidal surgery range from 0.4 to 2 percent, usually due to CSF leakage from a dural tear complicating the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cranial fractures can secondarily tear the dural mater and cause dural fistulas. Such fistulae sometimes produce visible leakage of CSF through the nose or ear but may also be clinically inapparent. Subsequent CSF leakage through these fistulae may be continuous, intermittent, occult or overt. Post-traumatic meningitis associated with a dural fistula can occur within days, weeks, months, or rarely even years after head injury [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/18\">",
"     18",
"    </a>",
"    ]. The majority of late infections occurring out of hospital in neurosurgical patients months to years after operation are due to Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both temporary epidural catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/20\">",
"     20",
"    </a>",
"    ] and tunneled intraspinal catheter systems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/21\">",
"     21",
"    </a>",
"    ] can be complicated by meningitis. The vast majority of such infections do not involve the meninges and are due to skin flora or S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. However, gram-negative bacilli can also cause these infections. In two large surveys of the outcome of epidural catheters and tunneled intraspinal catheters, 14 infected patients were identified, only three of whom had meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Gram-negative bacilli (in both cases P. aeruginosa) were responsible for two of these 14 infections. Rarely, gram-negative meningitis can arise from direct extension from an infective focus such as mastoiditis or chronic sinusitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/18\">",
"     18",
"    </a>",
"    ] or from cochlear implants in children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Spontaneous gram-negative meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gram-negative organisms are an infrequent cause of community-acquired meningitis, accounting for only 9 of 253 episodes (3.6 percent) in a report from the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/14\">",
"     14",
"    </a>",
"    ] and 5 of 696 episodes (0.7 percent) in a report from the Netherlands [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spontaneous nontraumatic gram-negative bacillary meningitis is usually community-acquired (two-thirds of cases in one series) and most frequently occurs in patients who are elderly or have underlying conditions, such as alcohol-induced cirrhosis, diabetes, malignancy, splenectomy, and glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,5,11\">",
"     4,5,11",
"    </a>",
"    ]. Instrumentation of the urinary tract was the most common identified portal of entry in cases of spontaneous meningitis in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the gram-negative bacilli that cause meningitis, the most frequently implicated organisms are E. coli, Klebsiella pneumoniae, P. aeruginosa and Acinetobacter. E. coli and Klebsiella account for more than 50 percent of cases of gram-negative bacillary meningitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. Infrequent pathogens include Citrobacter species, Serratia marcescens, Enterobacter species and Proteus mirabilis.",
"   </p>",
"   <p>",
"    As noted above, E. coli is the most common cause of gram-negative meningitis in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, E. coli caused 53 percent of cases of gram-negative bacillary meningitis in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. E. coli is also a common cause in adults of both spontaneous gram-negative bacillary meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ] and of meningitis complicating neurosurgical procedures. One study highlighted the connection between E. coli meningitis and bowel perforation in patients with ventriculoperitoneal shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Klebsiella meningitis occurs more often in elderly patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"     24",
"    </a>",
"    ], and has been reported in patients with alcoholic liver disease, diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/26\">",
"     26",
"    </a>",
"    ], and transfusion-dependent thalassemia major [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/27\">",
"     27",
"    </a>",
"    ]. Coinfection can occur with other pathogens such as Enterobacter [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013768#H6013768\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Meningitis/brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among cases of gram-negative meningitis in Taiwan, Klebsiella was the most common pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ]. In two series from Taiwan, K. pneumoniae and K. oxytoca accounted for 13 and 2.3 percent of culture-proven cases, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, particularly in Taiwan and other countries in Southeast Asia, K. pneumoniae meningitis can represent a metastatic infection from community-acquired primary liver abscess. This relationship is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29176?source=see_link&amp;anchor=H8#H8\">",
"     \"Invasive liver abscess syndrome caused by Klebsiella pneumoniae\", section on 'Metastatic infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=see_link&amp;anchor=H6013768#H6013768\">",
"     \"Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection\", section on 'Meningitis/brain abscess'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Enterobacter meningitis occurs predominantly among neurosurgical patients. In a matched case-control study, external CSF drainage devices and isolation of Enterobacter spp. from a non-CSF culture, were independent risk factors for Enterobacter meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pseudomonas meningitis can occur as a rare complication of chronic cranial osteomyelitis and mastoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"     24",
"    </a>",
"    ] or following trauma. Serratia marcescens may also occur after trauma but in one review was recognized as an important pathogen following surgery involving the ear canal [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acinetobacter spp. are an infrequent of cause of nosocomial meningitis and a rare cause of community-acquired meningitis. Risk factors for nosocomial meningitis include neurosurgical procedures, cerebrospinal fluid (CSF) leak, prior antibiotic therapy, and intracranial hemorrhage. Multidrug resistance is an increasing problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link\">",
"     \"Treatment and prevention of Acinetobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=see_link&amp;anchor=H1211160#H1211160\">",
"     \"Treatment and prevention of Acinetobacter infection\", section on 'Meningitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Salmonella is a prevalent cause of meningitis among infants in Taiwan, and infection carries with it a high risk of neurologic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrobacter diversus is an occasional cause of meningitis in newborn infants but is associated with substantial morbidity and mortality. One-third of neonates with meningitis due to Citrobacter die, and the majority of survivors have significant neurologic sequelae [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/32\">",
"     32",
"    </a>",
"    ]. Brain abscess also occurs in up to three-quarters of cases of neonatal C. diversus meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. C. freundii and C. diversus very rarely cause meningitis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/34\">",
"     34",
"    </a>",
"    ]. In the scattered cases reported to date, predisposing conditions included trauma, alcoholism and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ochrobactrum anthropi was found to be the cause of meningitis in three pediatric patients who had received pericardial dural grafts. Presumably these infections arose from contamination of the pericardial grafts during processing or freezing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/35\">",
"     35",
"    </a>",
"    ]. Other gram-negative bacilli which rarely cause meningitis include: Aeromonas, Moraxella, Flavobacterium, Bacteroides, Fusobacterium, Pasteurella [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"     24",
"    </a>",
"    ], and Capnocytophaga [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/36\">",
"     36",
"    </a>",
"    ]. Pasteurella multocida meningitis has been reported in infants who were licked by family pets [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of postoperative gram-negative meningitis occur 10 or more days after surgery (range 1 to 20 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ]. The time interval is similar in infants, with a mean of 5.5 days following surgery (range 1 to 15 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. However, meningitis following transsphenoidal surgery appears to develop more rapidly with a mean of 2.8 days (range, two to four days) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/17\">",
"     17",
"    </a>",
"    ]. Depending upon the etiologic organism, this interval may be quite variable. As an example, the period between neurosurgery and the onset of K. oxytoca meningitis ranged from as short as two days to 40 months in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever and signs of CNS infection such as altered mental status, seizures, or nuchal rigidity are present in most patients with gram-negative meningitis and can be dramatic [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/5\">",
"     5",
"    </a>",
"    ]. However, gram-negative meningitis following neurosurgical procedures may be subtle and insidious in onset [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Signs can be obscured by the use of corticosteroid therapy for the control of intracranial hypertension. The diagnosis can also be missed because other post-operative sources or complications may be deemed responsible for fever or neurologic abnormalities.",
"   </p>",
"   <p>",
"    Furthermore, in elderly patients with underlying medical illness, such as diabetes mellitus and cardiac disease, confusional state may be the only presenting feature [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/39\">",
"     39",
"    </a>",
"    ]. Fever is usually present in this group, but headache and meningeal signs may be absent.",
"   </p>",
"   <p>",
"    Fever, irritability, seizures, lethargy and poor feeding are the usual clinical clues to the presence of meningitis in infants, including infection caused by gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. Bulging of the fontanelle may suggest the diagnosis of meningitis in such children.",
"   </p>",
"   <p>",
"    Septic shock is a serious complication of gram-negative meningitis and is associated with a high mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ]. Septic shock appears to be more common in cases of spontaneous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ] for reasons which are not clear.",
"   </p>",
"   <p>",
"    Gram-negative meningitis commonly is accompanied by bacteremia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series of 30 adults with gram-negative meningitis following neurosurgery or arising spontaneously, 43 percent of patients were bacteremic [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"       4",
"      </a>",
"      ]. The mortality rate was 53 percent in the bacteremic patients compared to 12 percent among those without accompanying bacteremia.",
"     </li>",
"     <li>",
"      In another study of gram-negative bacillary meningitis in neonates and infants over a twenty-one year period, bacteremia was present in 55 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third survey of 77 adults, the majority of whom had spontaneous gram-negative meningitis, identified a bacteremia in 58 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bacteremia was not associated with a higher mortality in these latter two studies [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2,11\">",
"       2,11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Outcome of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality due to gram-negative bacillary meningitis in adults and children has ranged from 40 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. Patients with spontaneous meningitis typically have a more fulminant course with a higher prevalence of bacteremia, shock, and death [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,28\">",
"     4,28",
"    </a>",
"    ]. As an example, 9 of 30 patients (30 percent) died in one case series; two-thirds of these fatalities occurred in patients with spontaneous meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"     4",
"    </a>",
"    ]. In another study, 28 percent of patients died despite treatment with appropriate antibiotics, and the mortality rate was again higher in patients with spontaneous gram-negative bacillary meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, in the large pediatric case series, the mortality rate was higher in gram-negative bacillary meningitis which followed surgery than in those cases which arose spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"     2",
"    </a>",
"    ]. The case fatality rate in the former group was 27 percent and almost 50 percent lower in the latter patients.",
"   </p>",
"   <p>",
"    Important independent prognostic factors in predicting the outcome of gram-negative bacillary meningitis are use of appropriate antimicrobial therapy and the presence of septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ]. In virtually all studies, one of the most important factors predicting survival is the state of consciousness at the time of admission [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/40\">",
"     40",
"    </a>",
"    ]. In a large series from Massachusetts, patients who were unresponsive or responsive only to pain had a 49 percent mortality rate compared to 16 percent for those who were alert or only lethargic (P=0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate for these infections, even for pathogens such as K. pneumoniae and P. aeruginosa, may be declining. The mortality rate for gram-negative meningitis due to these two pathogens was 91 and 84 percent, respectively, more than a decade ago [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"     24",
"    </a>",
"    ] compared to 56 and 36 percent, respectively, in a more contemporary series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"     11",
"    </a>",
"    ]. Age over 60 years, diabetes mellitus and severe neurologic deficits have been identified as poor prognostic factors in K. pneumoniae meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/28\">",
"     28",
"    </a>",
"    ]. E. coli is the gram-negative bacillus most associated with death in a few different series [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/4,11,24\">",
"     4,11,24",
"    </a>",
"    ]. However, the introduction of third generation cephalosporins has been postulated to account for the decrease in mortality rate among adults with gram-negative bacillary meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Complications of meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible complications and sequelae from gram-negative bacillary meningitis are numerous, especially in infants and children, just like for meningitis due to other organisms. Seizures occurring before or some time during hospitalization have been predictive of mortality or neurologic sequelae in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/40\">",
"     40",
"    </a>",
"    ]. In addition, delayed sterilization of CSF cultures following commencement of therapy for meningitis has been associated with neurologic sequelae including hearing loss [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .) Complications include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16600/abstract/2,11,41\">",
"     2,11,41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ventriculitis",
"     </li>",
"     <li>",
"      Subdural effusion",
"     </li>",
"     <li>",
"      Brain abscess",
"     </li>",
"     <li>",
"      Syndrome of inappropriate antidiuretic hormone secretion",
"     </li>",
"     <li>",
"      Hydrocephalus",
"     </li>",
"     <li>",
"      Seizure disorder",
"     </li>",
"     <li>",
"      Spastic paralysis",
"     </li>",
"     <li>",
"      Mental retardation",
"     </li>",
"     <li>",
"      Hearing deficit",
"     </li>",
"     <li>",
"      Metastatic septic abscesses",
"     </li>",
"     <li>",
"      Acute disseminated encephalomyelitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14428829\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gram-negative bacilli are important pathogens in neonatal or infant meningitis and in nosocomial meningitis, often as a complication of trauma or neurosurgery. Despite the increasing use of complex neurosurgical techniques, nosocomial gram-negative bacillary meningitis remains a relatively uncommon infection. Spontaneous nontraumatic gram-negative bacillary meningitis in adults is rare, most frequently occurs in patients who are elderly or have other comorbidities, and is associated with urinary tract instrumentation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gram-negative bacilli can seed the cerebrospinal fluid secondary to bacteremia, trauma, and surgery. Subsequent meningitis can develop as a result of bacterial multiplication and induction of inflammation in the subarachnoid and ventricular space, followed by progression of inflammation and development of neuronal damage. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Escherichia coli and Klebsiella pneumoniae account for the majority of cases of gram-negative bacillary meningitis in adults. Other important, less frequent pathogens include Pseudomonas aeruginosa, Acinetobacter, Enterobacter, and Serratia. E. coli is the most common cause of gram-negative meningitis in infants. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of meningitis, such as fever, altered mental status, seizures, and nuchal rigidity, are often dramatic in cases of spontaneous gram-negative bacillary meningitis, but may be insidious in onset or obscured by corticosteroid therapy in nosocomial cases. Confusional state may be the only presenting feature in elderly patients with underlying medical illness. Fever is usually present in this group, but headache and meningeal signs may be absent. In infants, fever, irritability, seizures, lethargy, poor feeding, and a bulging fontanelle are often clinical clues of meningitis. Gram-negative bacillary meningitis is commonly accompanied by bacteremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality due to gram-negative bacillary meningitis in adults and children has ranged from 40 to 80 percent. Important negative prognostic factors include an altered state of consciousness at presentation (unresponsive or responsive to pain only), failure of timely administration of appropriate antimicrobial therapy, and the presence of septic shock. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Outcome of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications are similar to those of meningitis of any bacterial etiology and include ventriculitis, brain or metastatic abscesses, seizures, and hearing, cognitive, or motor deficits. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Complications of meningitis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/1\">",
"      Theccanat G, Hirschfield L, Isenberg H. Serratia marcescens meningitis. J Clin Microbiol 1991; 29:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/2\">",
"      Unhanand M, Mustafa MM, McCracken GH Jr, Nelson JD. Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr 1993; 122:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/3\">",
"      Wolff MA, Young CL, Ramphal R. Antibiotic therapy for enterobacter meningitis: a retrospective review of 13 episodes and review of the literature. Clin Infect Dis 1993; 16:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/4\">",
"      Berk SL, McCabe WR. Meningitis caused by gram-negative bacilli. Ann Intern Med 1980; 93:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/5\">",
"      Rahal JJ, Simberkoff MS. Host defense and antimicrobial therapy in adult gram-negative bacillary meningitis. Ann Intern Med 1982; 96:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/6\">",
"      Korinek AM, Baugnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. Neurosurgery 2006; 59:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/7\">",
"      Harder E, M&oslash;ller K, Skinh&oslash;j P. Enterobacteriaceae meningitis in adults: a review of 20 consecutive cases 1977-97. Scand J Infect Dis 1999; 31:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/8\">",
"      Simberkoff MS, Moldover NH, Rahal J Jr. Absence of detectable bactericidal and opsonic activities in normal and infected human cerebrospinal fluids. A regional host defense deficiency. J Lab Clin Med 1980; 95:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/9\">",
"      Landesman SH, Cherubin CE, Corrado ML. Gram-negative bacillary meningitis. New therapy and changing concepts. Arch Intern Med 1982; 142:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/10\">",
"      Leib SL, T&auml;uber MG. Pathogenesis of bacterial meningitis. Infect Dis Clin North Am 1999; 13:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/11\">",
"      Lu CH, Chang WN, Chuang YC, Chang HW. The prognostic factors of adult gram-negative bacillary meningitis. J Hosp Infect 1998; 40:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/12\">",
"      Mulder CJ, van Alphen L, Zanen HC. Neonatal meningitis caused by Escherichia coli in The Netherlands. J Infect Dis 1984; 150:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/13\">",
"      Peter G, Nelson JS. Factors affecting neonatal E. coli K1 rectal colonization. J Pediatr 1978; 93:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/14\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/15\">",
"      Huang CR, Lu CH, Chang WN. Adult Enterobacter meningitis: a high incidence of coinfection with other pathogens and frequent association with neurosurgical procedures. Infection 2001; 29:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/16\">",
"      Filka J, Huttova M, Tuharsky J, et al. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999; 88:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/17\">",
"      Haile-Mariam T, Laws E, Tuazon CU. Gram-negative meningitis associated with transsphenoidal surgery: case reports and review. Clin Infect Dis 1994; 18:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/18\">",
"      Peeters A, Vandercam B, Sindic CJ, et al. Community-acquired Serratia marcescens meningitis. J Infect 1997; 35:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/19\">",
"      Buckwold FJ, Hand R, Hansebout RR. Hospital-acquired bacterial meningitis in neurosurgical patients. J Neurosurg 1977; 46:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/20\">",
"      Pegues DA, Carr DB, Hopkins CC. Infectious complications associated with temporary epidural catheters. Clin Infect Dis 1994; 19:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/21\">",
"      Byers K, Axelrod P, Michael S, Rosen S. Infections complicating tunneled intraspinal catheter systems used to treat chronic pain. Clin Infect Dis 1995; 21:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/22\">",
"      Reefhuis J, Honein MA, Whitney CG, et al. Risk of bacterial meningitis in children with cochlear implants. N Engl J Med 2003; 349:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/23\">",
"      van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med 2004; 351:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/24\">",
"      Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults. Am J Med 1981; 71:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/25\">",
"      Ibrahim AW. E. coli meningitis as an indicator of intestinal perforation by V-P shunt tube. Neurosurg Rev 1998; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/26\">",
"      Chang WN, Lu CH, Chang CS, Huang CR. Community-acquired spontaneous bacterial meningitis in patients with alcoholic liver disease. J Formos Med Assoc 2003; 102:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/27\">",
"      Li CK, Shing MM, Chik KW, et al. Klebsiella pneumoniae meningitis in thalassemia major patients. Pediatr Hematol Oncol 2001; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/28\">",
"      Tang LM, Chen ST. Klebsiella pneumoniae meningitis: prognostic factors. Scand J Infect Dis 1994; 26:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/29\">",
"      Tang LM, Chen ST. Klebsiella oxytoca meningitis: frequent association with neurosurgical procedures. Infection 1995; 23:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/30\">",
"      Parodi S, Lechner A, Osih R, et al. Nosocomial enterobacter meningitis: risk factors, management, and treatment outcomes. Clin Infect Dis 2003; 37:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/31\">",
"      Chang CJ, Chang WN, Huang LT, et al. Bacterial meningitis in infants: the epidemiology, clinical features, and prognostic factors. Brain Dev 2004; 26:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/32\">",
"      Eppes SC, Woods CR, Mayer AS, Klein JD. Recurring ventriculitis due to Citrobacter diversus: clinical and bacteriologic analysis. Clin Infect Dis 1993; 17:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/33\">",
"      Anoop P, Anjay MA, Vincent J, Girija B. Fulminant citrobacter meningitis with multiple periventricular abscesses in a three-month-old infant. Braz J Infect Dis 2003; 7:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/34\">",
"      Tang LM, Chen ST, Lui TN. Citrobacter meningitis in adults. Clin Neurol Neurosurg 1994; 96:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/35\">",
"      Chang HJ, Christenson JC, Pavia AT, et al. Ochrobactrum anthropi meningitis in pediatric pericardial allograft transplant recipients. J Infect Dis 1996; 173:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/36\">",
"      Pers C, Gahrn-Hansen B, Frederiksen W. Capnocytophaga canimorsus septicemia in Denmark, 1982-1995: review of 39 cases. Clin Infect Dis 1996; 23:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/37\">",
"      Perrin I, Blanc P, Karam T, Carbajal R. [Meningitis and osteitis caused by Pasteurella multocida in a three-month-old infant]. Arch Pediatr 2003; 10:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/38\">",
"      Wade T, Booy R, Teare EL, Kroll S. Pasteurella multocida meningitis in infancy - (a lick may be as bad as a bite). Eur J Pediatr 1999; 158:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/39\">",
"      Gorse GJ, Thrupp LD, Nudleman KL, et al. Bacterial meningitis in the elderly. Arch Intern Med 1984; 144:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/40\">",
"      Kaplan SL. Clinical presentations, diagnosis, and prognostic factors of bacterial meningitis. Infect Dis Clin North Am 1999; 13:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16600/abstract/41\">",
"      Proulx NL, Freedman MS, Chan JW, et al. Acute disseminated encephalomyelitis associated with Pasteurella multocida meningitis. Can J Neurol Sci 2003; 30:155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1302 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-78.134.254.52-5CE980D4F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16600=[""].join("\n");
var outline_f16_13_16600=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14428829\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Neonatal meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Nosocomial meningitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Spontaneous gram-negative meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Outcome of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Complications of meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14428829\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/47/7928?source=related_link\">",
"      Clinical features and diagnosis of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38426?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Klebsiella pneumoniae infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25930?source=related_link\">",
"      Diagnosis and treatment of gram-negative bacillary meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/50/27432?source=related_link\">",
"      Epidemiology of Neisseria meningitidis infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31335?source=related_link\">",
"      Epidemiology of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/31/29176?source=related_link\">",
"      Invasive liver abscess syndrome caused by Klebsiella pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7688?source=related_link\">",
"      Microbiology and pathobiology of Neisseria meningitidis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31656?source=related_link\">",
"      Neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23402?source=related_link\">",
"      Treatment and prevention of Acinetobacter infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16601="Depression in adults: Supportive psychotherapy";
var content_f16_13_16601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Depression in adults: Supportive psychotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Julie Lord, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Kimberly D McLaren, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Mitchell Levy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16601/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/13/16601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1193448870\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive psychotherapy is used to treat depression by improving self-esteem, psychological functioning, and adaptive skills [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapy focuses upon current, problematic relationships and maladaptive patterns of behavior and emotional responses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Supportive psychotherapy is used to treat a variety of psychiatric illnesses other than depression, including anxiety disorders, schizophrenia, substance use disorders, and personality disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/3\">",
"     3",
"    </a>",
"    ]. A survey of psychiatrists in 1998 found that 36 percent of them used supportive psychotherapy, often in conjunction with pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews supportive psychotherapy for treating depression in adults. The initial treatment of depression; treatment of resistant depression; treatment of late-life depression; and diagnosis, prognosis, epidemiology, pathogenesis, and neurobiology of depression are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=see_link\">",
"       \"Diagnosis and management of late-life depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=see_link\">",
"       \"Unipolar depression in adults: Prognosis and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=see_link\">",
"       \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193448877\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive psychotherapy is used as both a primary and adjunctive treatment with pharmacotherapy to treat depression. Supportive psychotherapy is suitable across a broad range of symptom severity and psychosocial functioning. Level of symptom severity and functioning are usually classified as [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/3,5-8\">",
"     3,5-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High &ndash; mild symptoms and impairment such as dysphoria, mild insomnia, distracted at work, and occasional lapses in household duties",
"     </li>",
"     <li>",
"      Moderate &ndash; moderate symptoms and impairment such as chronic dysphoria, flat affect, circumstantial speech, estrangement from family, few friends, and inability to work &nbsp;",
"     </li>",
"     <li>",
"      Low &ndash; serious symptoms and impairment such as psychosis, suicidality, alienation from family, no friends, difficulty retaining housing &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The level of symptom severity and functioning is assessed at the beginning and throughout treatment, and determines the specific treatment interventions used by the clinician. (See",
"    <a class=\"local\" href=\"#H1193448921\">",
"     'Assessment'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1193448944\">",
"     'Therapeutic interventions'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    The patient must have the necessary motivation and interest, cognitive capacity, and energy required to participate in any type of psychotherapy. However, supportive psychotherapy does not require the high level of psychological-mindedness needed for psychodynamic psychotherapy, and does not require the level of motivation necessary to complete homework outside of the treatment sessions that is needed for cognitive-behavioral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon our clinical experience, mild to moderate depression can be treated with supportive psychotherapy alone. Patients with moderate to severe depression, especially moderate to severe suicidal ideation or moderate to severe neurovegetative symptoms (decreased sleep, appetite, and energy), require pharmacotherapy in addition to supportive psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Practice guidelines from the American Psychiatric Association, National Institute for Clinical Excellence, and the Canadian Network for Mood and Anxiety Treatments do not suggest supportive psychotherapy as a treatment for depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. It&rsquo;s not clear why, but it may be that the guideline authors view supportive psychotherapy as a subset of psychodynamic psychotherapy, which the guidelines do suggest as a treatment for depression. (See",
"    <a class=\"local\" href=\"#H1193448891\">",
"     'Theoretical foundation'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193448891\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is thought that supportive psychotherapy works by improving self-esteem, psychological functioning, and adaptive skills [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,5,14\">",
"     2,5,14",
"    </a>",
"    ]. The conceptual basis for supportive psychotherapy overlaps with psychodynamic psychotherapy and other psychotherapies [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,15,16\">",
"     2,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is hypothesized that supportive psychotherapy treats depression by improving [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,5,14\">",
"     2,5,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Self-esteem &ndash; patient&rsquo;s sense of self-regard, efficacy, confidence, and hope &nbsp;",
"     </li>",
"     <li>",
"      Psychological (ego) functioning &ndash; reality testing, cognitive abilities, capacity to organize thoughts and behavior, affect regulation, capacity to relate to others, and morals",
"     </li>",
"     <li>",
"      Adaptive skills &ndash; behaviors associated with effective functioning with family, friends, and coworkers &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Assessment of events is a psychological function, whereas the behavioral response to the assessment is an adaptive skill; self-esteem usually depends upon both [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,7,17\">",
"     2,7,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authorities think supportive psychotherapy is a type of psychodynamic psychotherapy because of overlap in how they conceptualize and treat depression. However, the differences between the two therapies justify viewing them as distinct. The primary difference is that supportive psychotherapy focuses upon current relationships and conscious issues [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,8,15,18-20\">",
"     5,7,8,15,18-20",
"    </a>",
"    ], while psychodynamic psychotherapy focuses upon childhood experiences, past unresolved conflicts, and previous relationships, as well as unconscious mental states and processes (including transference, countertransference, defense mechanisms, and resistance) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link&amp;anchor=H87035537#H87035537\">",
"     \"Depression in adults: Psychodynamic psychotherapy\", section on 'Fundamental concepts and processes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both therapies use many of the same interventions, which form a continuum [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. At one end are techniques emphasized in supportive psychotherapy that directly support the patient and maintain adaptive defenses. At the other end are techniques emphasized in psychodynamic psychotherapy that increase the patient&rsquo;s insight through exploration and interpretation of the patient&rsquo;s behavior. (See",
"    <a class=\"local\" href=\"#H1193448944\">",
"     'Therapeutic interventions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link&amp;anchor=H114301#H114301\">",
"     \"Depression in adults: Psychodynamic psychotherapy\", section on 'Therapeutic interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supportive psychotherapy also draws upon ideas and techniques of other psychotherapies, including cognitive-behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. CBT is based upon the theory that maladaptive thoughts and behaviors lead to psychopathology. The clinician addresses these dysfunctional cognitions and the patient tries to change the resulting problematic behavior. Supportive psychotherapy also uses elements of behavioral activation, problem-solving therapy, and interpersonal therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193448921\">",
"    <span class=\"h1\">",
"     ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial patient assessment consists of the history and mental status examination [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The clinician diagnoses the depressive syndrome; identifies any precipitating problems; evaluates the patient&rsquo;s the level of functioning, self-esteem, psychological functioning, and adaptive skills; and establishes the patient&rsquo;s goals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,26\">",
"     5,7,26",
"    </a>",
"    ]. Progress is determined by periodically reassessing the patient during the course of treatment.",
"   </p>",
"   <p>",
"    The clinician asks about the patient&rsquo;s current life circumstances and prior experiences, and how the patient reacts and copes with stress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5\">",
"     5",
"    </a>",
"    ]. Suggested questions include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Can the patient perceive and appraise events accurately?",
"     </li>",
"     <li>",
"      Does the patient have at least one durable, reciprocal relationship?",
"     </li>",
"     <li>",
"      Can the patient experience and tolerate a wide range of affects?",
"     </li>",
"     <li>",
"      Does the patient tolerate frustration?",
"     </li>",
"     <li>",
"      Can the patient control impulses?",
"     </li>",
"     <li>",
"      Can the patient work toward goals, delay gratification, and enjoy leisure?",
"     </li>",
"     <li>",
"      Is the patient guided by internalized morals and ideals?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician observes how the patient relates to the clinician, because this reflects behavior outside of therapy and suggests what types of reactions the patient evokes in others.",
"   </p>",
"   <p>",
"    The clinician also observes the patient&rsquo;s defense mechanisms, which reveal how the patient unconsciously copes with anxiety and conflicts. Defenses exist on a continuum from immature (eg, projection, denial, and splitting) to mature (eg, suppression and humor). Defense mechanisms are discussed further within the context of psychodynamic psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link&amp;anchor=H20761777#H20761777\">",
"     \"Depression in adults: Psychodynamic psychotherapy\", section on 'Defense mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714936\">",
"    <span class=\"h2\">",
"     Standardized, self-report rating scale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients complete a self-report, standardized, depression rating scale prior to the beginning of each session. We suggest the widely-used Patient Health Questionnaire &ndash; Nine Item (PHQ-9), which is a well-validated depression self-report scale (",
"    <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Alternatives include the Clinically Useful Depression Outcome Scale (CUDOS) (",
"    <a class=\"graphic graphic_form graphicRef65101 \" href=\"UTD.htm?25/29/26065\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] and the Quick Inventory of Depressive Symptoms &ndash; Self Report 16 Item (QIDS-SR16) (www.ids-qids.org) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The rating scale quantifies the severity of the patient's depression and enables the clinician to track improvement over time. In addition, the scale educates patients about the clinical features of depression so that patients can learn to recognize them on their own.",
"   </p>",
"   <p>",
"    Using scales to monitor treatment of depressed patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=see_link&amp;anchor=H100014116#H100014116\">",
"     \"Using scales to monitor symptoms and treatment of depression (measurement based care)\", section on 'Self-report scales in the public domain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193448928\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive psychotherapy consists of a number of general principles and specific interventions. However, treatment depends less upon any specific maneuver and more upon the therapeutic relationship between the patient and clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4043939\">",
"    <span class=\"h2\">",
"     General treatment principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy is directed towards improving self-esteem, psychological functioning, and adaptive skills [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,33\">",
"     5,33",
"    </a>",
"    ]. Improvement in one domain promotes improvement in the other two domains. (See",
"    <a class=\"local\" href=\"#H1193448891\">",
"     'Theoretical foundation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Supportive psychotherapy focuses upon current problematic relationships and maladaptive patterns of conscious behavior and emotional responses [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. The purpose is to help patients connect their behavior to resulting events or the reactions of others, shift the locus of control to the patient, and increase personal responsibility [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,5,8,14,18,19,33\">",
"     2,5,8,14,18,19,33",
"    </a>",
"    ]. Although therapy focuses upon the &ldquo;here-and-now,&rdquo; earlier experiences may be discussed to understand the origin of current maladaptive behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,34\">",
"     5,34",
"    </a>",
"    ]. This also creates a coherent biography to promote increased self-understanding.",
"   </p>",
"   <p>",
"    The clinician balances the patient&rsquo;s need for support with the desire for competence and autonomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,14,15,34\">",
"     5,14,15,34",
"    </a>",
"    ]. A patient overwhelmed by stress may need comforting to regain equilibrium and function better, and at other times, might require an encouraging &ldquo;push&rdquo; to try something new [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/14,34,35\">",
"     14,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A conversational approach is used [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinician is active, answers questions, takes positions, and directs the session to keep the emotional intensity at manageable levels [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,33\">",
"     5,7,33",
"    </a>",
"    ]. Anxiety-provoking, prolonged silences are avoided, as are challenging questions that put the patient on the spot [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinician acts like a &ldquo;real person&rdquo; rather than striving to be a neutral, anonymous &ldquo;blank screen.&rdquo; Clinicians respond to personal questions from the patient within appropriate social conventions of privacy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2\">",
"     2",
"    </a>",
"    ]. Self-disclosure should have a therapeutic rationale, such as validating reality, modeling behavior, teaching, and fostering the therapeutic alliance and the patient&rsquo;s sense of autonomy.",
"   </p>",
"   <p>",
"    Supportive psychotherapy provides a &ldquo;holding environment,&rdquo; meaning that treatment is marked by emotional safety, trust, consistency, and structure [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/15,17,36\">",
"     15,17,36",
"    </a>",
"    ]. This promotes corrective emotional experiences, in which the patient learns to tolerate situations that were previously intolerable. The clinician expresses empathy to corroborate the emotional experience of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. The clinician also conveys interest, respect, acceptance, and approval of the patient to promote a positive therapeutic alliance. This helps the patient to identify with the clinician, become more amenable to specific interventions, and predicts a positive outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. In addition, the clinician solicits feedback from the patient to ensure that the clinician correctly understands what the patient says. The therapeutic alliance is discussed further within the context of psychodynamic psychotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=see_link&amp;anchor=H114251#H114251\">",
"     \"Depression in adults: Psychodynamic psychotherapy\", section on 'Therapeutic alliance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a rupture develops in the therapeutic alliance, the clinician promptly attempts to repair the alliance and prevent the patient from prematurely quitting treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,8,14,15\">",
"     5,7,8,14,15",
"    </a>",
"    ]. An open and nondefensive discussion of the clinician&rsquo;s actions can help dissipate the patient&rsquo;s negative feelings [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. In addition, the relationship between the clinician and the patient may be examined to better understand and ameliorate problems in the patient&rsquo;s other relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/14,33\">",
"     14,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1841864\">",
"    <span class=\"h2\">",
"     Logistics and structure of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several logistical aspects that determine the course of treatment. These include the number, frequency, and duration of sessions, which is flexible and determined by the intensity of symptoms, chronicity of the depressive illness, and rate of progress [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,8\">",
"     5,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At the beginning of treatment, the clinician and patient should set specific, realistic outcome goals, and during the course of treatment discuss progress. The clinician should discuss what will occur during the sessions and what the patient is expected to do, as well as the policy for tardiness, missed appointments, telephone calls, emergencies, and payment [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapy is often open-ended and continues until symptoms are reduced or eliminated, and functioning is restored [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. However, based upon our clinical experience, if little or no progress is made within four months, the therapy should be stopped and the treatment plan revised. A randomized trial assigned 90 patients with moderate to severe major depression to 8 or 16 sessions of supportive psychotherapy as adjunctive treatment to pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/38\">",
"     38",
"    </a>",
"    ]. Remission at week 24 did not differ significantly between patients who received psychotherapy for 8 weeks compared with 16 weeks (33 versus 29 percent), nor did social functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of sessions depends upon the stage of treatment. Actively depressed patients are typically treated once a week until the illness resolves. As the end of treatment approaches, therapy can be tapered by increasing the interval between visits. At the end of treatment, clinicians should inform patients that if symptoms recur, patients can return and be re-assessed for resuming supportive psychotherapy. Thus, the treatment relationship is open-ended, rather than formally terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maintenance therapy is used to delay or prevent recurrence of major depression, and should be considered for lower functioning patients with previous episodes and hospitalizations. Euthymic patients in maintenance treatment may be seen as often as once or twice per month or as infrequently as a few times per year, depending upon their stability and needs. Lower functioning patients or patients with chronic depression not responding to other types of treatment (such as pharmacotherapy), are generally seen one or two times per month to preserve psychosocial functioning and prevent further deterioration. &nbsp;During times of crisis, the need for more frequent sessions often becomes apparent when the patient calls frequently between sessions, unable to cope with stress. However, there is no evidence that supportive psychotherapy is efficacious as maintenance treatment.",
"   </p>",
"   <p>",
"    Session duration is typically 45 to 50 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,8\">",
"     5,8",
"    </a>",
"    ]. However, some clinicians can provide elements of supportive therapy during medication management visits, which typically last for 15 to 20 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193448944\">",
"    <span class=\"h2\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The specific interventions listed below are used to treat depression by improving self-esteem, psychological functioning, and adaptive skills [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,8,14,17,19,20,33\">",
"     5,7,8,14,17,19,20,33",
"    </a>",
"    ]. Each intervention is aimed primarily at one of these three domains, but may secondarily improve the other domains.",
"   </p>",
"   <p>",
"    The clinician chooses specific therapeutic interventions based upon the patient&rsquo;s current symptoms, level of psychosocial functioning, and what occurs during a particular session [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. As treatment progresses, the patient&rsquo;s needs are reassessed and the clinician adjusts the interventions accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/14,34\">",
"     14,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H980023\">",
"    <span class=\"h3\">",
"     Self-esteem",
"    </span>",
"    &nbsp;&mdash;&nbsp;Self-esteem consists of the patient&rsquo;s beliefs about his inherent value and competence [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. Interventions to improve self-esteem include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Praise &ndash;",
"      </strong>",
"      Depressed patients often focus exclusively upon their shortcomings and failures [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,17\">",
"       5,7,17",
"      </a>",
"      ]. Praise helps these patients recognize their strengths and reinforces new, adaptive behavior. Praise should be grounded in the patient&rsquo;s values, and can be given for accomplishing a task, using an adaptive skill, or adopting a more emotionally mature strategy. The clinician should avoid offering insincere praise that is not deserved, because the patient can experience this as hollow and invalidating.",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Reassurance",
"      </strong>",
"      &ndash; Allaying the patient&rsquo;s fears with truthful information provides reassurance about negative self-appraisal and expectations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,17\">",
"       5,7,17",
"      </a>",
"      ]. The clinician should understand the patient&rsquo;s situation before offering reassurance. If reassurance is premature, the patient can feel dismissed and brushed off. In addition, clinicians should not mislead patients [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2\">",
"       2",
"      </a>",
"      ]. As an example, if a patient asks whether the depressive syndrome will remit, rather than simply saying, &ldquo;Yes,&rdquo; a more appropriate response is to state that, &ldquo;Most patients with depression get better.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Normalizing is a common form of reassurance that compares the patient to people whom the patient regards as normal. &ldquo;Many parents feel a loss when their kids leave home. That&rsquo;s why people talk about the &lsquo;empty nest syndrome;&rsquo; it&rsquo;s a tough transition for many people.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Encouragement",
"      </strong>",
"      &ndash; Encouragement is used to counteract passive inactivity and instill hope in patients feeling demoralized, defeated, or powerless [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,17\">",
"       2,17",
"      </a>",
"      ]. Transforming an overwhelming task into manageable, small steps encourages activity and promotes competence [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5\">",
"       5",
"      </a>",
"      ]. Pointing out instances of healthy, effective functioning also provides encouragement (and praise). The clinician should avoid contradicting the patient&rsquo;s viewpoint, which risks making the patient feel misunderstood [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5\">",
"       5",
"      </a>",
"      ]. Asking the patient what he thinks of the clinician&rsquo;s statements helps circumvent this problem.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Exhortation is a more insistent form of encouragement (and advice) that recommends a particular course of action [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"       17",
"      </a>",
"      ]. It is typically used with lower functioning patients. For example, &ldquo;We know that you feel worse when you don&rsquo;t exercise, and that you feel better overall when you do. So, I suggest that you start back at the gym on your old three times per week schedule.&rdquo; Exhortation should be used to encourage behavior that the patient can likely manage successfully. Otherwise, the patient may feel overwhelmed, discouraged, or criticized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H980139\">",
"    <span class=\"h3\">",
"     Psychological functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;This includes mental operations such as perceiving reality, regulating emotions, thought processes, capacity to organize thoughts and behavior, capacity to relate to others, and morals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ]. Interventions that improve psychological functioning will also decrease anxiety or increase awareness.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Structuring the environment",
"      </strong>",
"      &ndash; For lower functioning patients, the clinician should intervene when necessary to increase the amount of structure available to the patient [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/14,17,19\">",
"       14,17,19",
"      </a>",
"      ]. This includes talking with key people (eg, family, employers, or case managers) and directing the patient to necessary resources (eg, assistance with disability application or referrals to vocational rehabilitation). Patients who cannot maintain their own safety should be hospitalized.",
"     </li>",
"     <li>",
"      <strong>",
"       Naming the problem",
"      </strong>",
"      &ndash; Identifying and labelling the problem helps the patient conceptualize and understand it [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,17\">",
"       5,7,17",
"      </a>",
"      ]. The problem may then become less overwhelming and more amenable to change as the patient gains a greater sense of control. As an example, the clinician may use the term social isolation to describe the patient&rsquo;s social withdrawal and lack of interest in others.",
"     </li>",
"     <li>",
"      <strong>",
"       Rationalizing &ndash;",
"      </strong>",
"      The clinician suggests reasonable explanations for behavior, motives, or feelings that the patient finds unacceptable. As an example, maladaptive behavior can be rationalized as appropriate for an earlier stage of life [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,14\">",
"       5,7,14",
"      </a>",
"      ]. This tactic should be used in a manner that avoids arguing with the patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reframing is a type of rationalization in which the clinician proposes a different way of looking at events that the patient views as negative [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2\">",
"       2",
"      </a>",
"      ]. As an example, a mother may believe her toddler is losing interest in her because the child runs away from her. Reframing this involves explaining that the child feels secure enough to explore the world.",
"     </li>",
"     <li>",
"      Minimization is another type of rationalization in which the clinician suggests that the patient may be experiencing a small amount of an affect that is unacceptable and denied [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"       17",
"      </a>",
"      ]. As an example, if the patient denies feeling anger about an event, the clinician can ask, &ldquo;Perhaps you felt a little angry?&rdquo; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Clarification",
"      </strong>",
"      &ndash; The clinician organizes and paraphrases what the patient is discussing in a vague and uncertain manner [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2,5\">",
"       2,5",
"      </a>",
"      ]. The clinician&rsquo;s summarizing statement ensures that both parties agree on what is being discussed and demonstrates that the clinician is listening attentively. As an example, after the patient talks for several minutes about the boss&rsquo;s failure to notice his work and his wife&rsquo;s talking on the phone rather than with the patient, the clinician clarifies: &ldquo;It sounds like you are feeling ignored.&rdquo; Clarification illuminates the significance of what the patient is saying [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/18\">",
"       18",
"      </a>",
"      ]. Clarifications are often used and posed as questions. As an example, &ldquo;I wonder, are you really saying that you&rsquo;re not sure you want to keep your current job?&rdquo;",
"     </li>",
"     <li>",
"      <strong>",
"       Confrontation",
"      </strong>",
"      &ndash; This tactic makes the patient aware of something that is avoided, such as an unrecognized pattern of maladaptive behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"       17",
"      </a>",
"      ]. The clinician provides a rationale when confronting the patient to demonstrate empathy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/7\">",
"       7",
"      </a>",
"      ]. As an example, &ldquo;From our discussions, I have noticed that when you become romantically interested in people, you start avoiding them. I am bringing this up because you told me that you want to be in a relationship.&rdquo;",
"     </li>",
"     <li>",
"      <strong>",
"       Interpretation",
"      </strong>",
"      &ndash; An explanatory statement that links a feeling, thought, behavior, or symptom to its unconscious meaning or origin [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,15,19,20\">",
"       5,7,15,19,20",
"      </a>",
"      ]. Interpretation is used infrequently, and employed only to manage a rupture in the therapeutic alliance or to address maladaptive patterns of behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/7,18\">",
"       7,18",
"      </a>",
"      ]. As an example, the clinician may state, &ldquo;It seems that since I returned from vacation, you have not spoken about the painful problems you have with relationships. Is it harder to trust me? Do you feel like I abandoned you when I went away?&rdquo; The clinician modifies the interpretation by following the dictum, &ldquo;do not say everything that you know, only what will be helpful&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients are more likely to seriously consider an interpretation if it is presented as a possibility or hypothesis, rather than a definitive conclusion. In addition, interpretations should be used only after the clinician has gathered enough evidence to substantiate them.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H980147\">",
"    <span class=\"h3\">",
"     Adaptive skills",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adaptive skills consist of behaviors that lead to effective functioning with others. Interventions intended to increase functioning impart knowledge [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Advice",
"      </strong>",
"      &ndash; For higher functioning patients, the clinician should generally advise patients only about mental health issues [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,14\">",
"       5,7,14",
"      </a>",
"      ]. With lower functioning patients, specific and directive advice about daily life may be required. The clinician avoids nagging or critical comments, unwanted advice, and issues that patients can decide for themselves. In addition, clinicians should not impose their personal values upon the patient.",
"     </li>",
"     <li>",
"      <strong>",
"       Teaching",
"      </strong>",
"      &ndash; Teaching involves psychoeducation about the signs and symptoms of depression, different treatment options including medications, and prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/14\">",
"       14",
"      </a>",
"      ]. In addition, teaching includes principles for adaptive functioning that can be generalized and applied to different situations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Anticipatory guidance &ndash;",
"      </strong>",
"      This intervention consists of preparing patients for difficult situations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/2\">",
"       2",
"      </a>",
"      ]. The clinician and patient discuss step-by-step how to approach upcoming challenges. This includes anticipating problems, considering different plans of action, and rehearsing selected behaviors [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/5,7,14\">",
"       5,7,14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Modeling",
"      </strong>",
"      &ndash; The clinician uses his interactions with the patient to demonstrate adaptive behavior [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/17\">",
"       17",
"      </a>",
"      ]. The behavior is more likely to be adopted by patients who identify with the clinician. As an example, modeling occurs when the clinician makes a mistake and responds with honesty, humility, and resilience; or when the clinician makes an exception to the treatment rules and accommodates a patient in crisis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193449045\">",
"    <span class=\"h3\">",
"     Pharmacotherapy combined with supportive psychotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive psychotherapy is compatible with pharmacotherapy, and depressed patients are often treated with both [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/4\">",
"     4",
"    </a>",
"    ]. The two treatments can be started concurrently at the beginning of treatment, or monotherapy with either can be initiated at the outset and the other therapy added later [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/40\">",
"     40",
"    </a>",
"    ]. One clinician can provide both supportive psychotherapy and pharmacotherapy, with some sessions focused upon medication psychoeducation and side effects.",
"   </p>",
"   <p>",
"    Combination treatment has several theoretical benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/40\">",
"     40",
"    </a>",
"    ]. Pharmacotherapy may incompletely treat the depressive syndrome, and supportive psychotherapy can address residual symptoms, as well as psychosocial impairment, comorbidities (eg, substance use disorder or personality disorder), and adverse life circumstances (eg, trauma or losses). In addition, control of moderate or severe symptoms with pharmacotherapy may enable patients to make better use of psychotherapy. Psychotherapy may also improve adherence to treatment.",
"   </p>",
"   <p>",
"    If treatment is split and one clinician provides supportive psychotherapy and another clinician prescribes antidepressant medication, they need to work together to maintain consistency in the treatment plan. The clinicians should communicate with each other about any concerns that arise, and must have an agreement with each other and with the patient that there are no secrets between the two clinicians.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193449059\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research is mixed about the efficacy of supportive psychotherapy as a primary or adjunctive treatment for depression in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"     41",
"    </a>",
"    ]. A number of studies have found that supportive psychotherapy is either similar or inferior to other psychotherapies for treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/22,42\">",
"     22,42",
"    </a>",
"    ]. However, supportive psychotherapy may be comparable to pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, evidence is mixed as to whether adding supportive psychotherapy to pharmacotherapy improves treatment of depressive syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41,43\">",
"     41,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychotherapy trials, like pharmacotherapy trials, are methodologically variable. Some psychotherapy trials are rigorous and specify a priori hypotheses and analytic tests, use active psychotherapy comparators that control for the nonspecific aspects of psychotherapy, use standardized diagnostic criteria and outcome measures, carefully blind outcome ratings, develop manuals for the psychotherapies that are studied and measure adherence, and stratify patients on predetermined risk variables. Less meticulous studies use open-label designs, less rigorous comparators (eg, treatment as usual or waiting lists), or fail to adequately blind outcome ratings. Although it is commonly believed that blinding of patients in psychotherapy is less successful compared with pharmacotherapy trials, this has never been studied.",
"   </p>",
"   <p>",
"    Meta-analyses appear to overestimate the clinical effect for nearly all types of psychotherapy in treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. These inflated clinical effects seem to be the result of publication bias and study quality.",
"   </p>",
"   <p>",
"    The overlap between various psychotherapies makes it difficult to interpret some studies. It is sometimes not clear whether a type of psychotherapy constitutes supportive psychotherapy or an amalgam of different therapies. In addition, techniques from supportive psychotherapy have been adopted by other psychotherapies, and some studies have found that it is the supportive elements of other therapies that lead to beneficial outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193449068\">",
"    <span class=\"h2\">",
"     Supportive psychotherapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12494875\">",
"    <span class=\"h3\">",
"     Compared with treatment as usual",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial compared supportive psychotherapy (mean average of five weekly sessions) with treatment as usual in 30 patients with depressive symptoms, who were hospitalized for diabetic foot ulcers and not treated with antidepressants [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/49\">",
"     49",
"    </a>",
"    ]. Depressive symptoms improved significantly more in patients who received supportive therapy. Diabetic foot ulcers improved in both groups, suggesting that the effect of supportive psychotherapy could not be attributed solely to the patients&rsquo; physical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4773619\">",
"    <span class=\"h3\">",
"     Compared with other psychotherapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have found that supportive psychotherapy is either similar or inferior to other psychotherapies for treating depression: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of randomized trials included 30 comparisons of supportive psychotherapy with another type of psychotherapy for patients with mild to moderate depression, and found a significant but clinically marginal effect favoring all other types of psychotherapy combined together, compared with supportive psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/22\">",
"       22",
"      </a>",
"      ]. However, a separate analysis compared supportive psychotherapy with cognitive-behavioral therapy, and found no significant difference in improvement of depressive symptoms.",
"     </li>",
"     <li>",
"      A meta-analysis (2 randomized trials, 45 patients with major depression) found a significant, large clinical effect favoring behavioral therapy, compared with supportive psychotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial enrolled 221 patients with major depression and executive dysfunction, and found remission of depression occurred in significantly more patients who received problem-solving therapy, compared with supportive psychotherapy (46 versus 28 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial compared supportive psychotherapy with brief dynamic therapy in 88 patients with mild to moderate depression; both groups received 15 to 30 sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/51\">",
"       51",
"      </a>",
"      ]. At the six month follow-up, remission was observed in fewer patients who received supportive psychotherapy, compared with brief dynamic therapy (47 versus 76 percent). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17110555\">",
"    <span class=\"h3\">",
"     Compared with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that supportive psychotherapy may be comparable to pharmacotherapy for treating mild to moderate major depression. A meta-analysis of 3 randomized trials (142 patients) found the rate of remission at 6 months was comparable for supportive psychotherapy and pharmacotherapy (31 versus 24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3568988\">",
"    <span class=\"h2\">",
"     Supportive psychotherapy combined with pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is mixed evidence about the efficacy of supportive psychotherapy plus pharmacotherapy (combination treatment) for treating depression [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41,43\">",
"     41,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6147552\">",
"    <span class=\"h3\">",
"     Compared with pharmacotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear whether combination treatment is superior to pharmacotherapy alone for treating depressive syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one meta-analysis of three randomized trials, remission occurred in significantly more patients who received combination treatment compared with pharmacotherapy alone (40 versus 24 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"       41",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      A randomized trial in 128 patients with unipolar major depression found that after six months, remission occurred in significantly more patients who received combination treatment compared with pharmacotherapy alone (43 versus 23 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial enrolled 167 patients with unipolar major depression and found that improvement of blindly rated depressive symptoms was similar for combination treatment, compared with pharmacotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/53\">",
"       53",
"      </a>",
"      ]. However, scores on the self-report depression rating scale were significantly better for patients who received combination treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6147568\">",
"    <span class=\"h3\">",
"     Compared with psychotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not clear whether combination treatment is superior to supportive psychotherapy alone for treating depression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of three randomized trials compared combination treatment with supportive psychotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"       41",
"      </a>",
"      ]. The rate of remission for combination treatment was comparable to supportive psychotherapy (40 versus 31 percent), as was the rate of attrition (28 versus 24 percent).",
"     </li>",
"     <li>",
"      A randomized trial enrolled depressed patients infected with the human immunodeficiency virus (HIV) and found that depressive symptoms improved significantly more in patients who received combination treatment, compared with supportive psychotherapy alone [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16601/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1193449145\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive psychotherapy is used to treat depression by improving self-esteem, psychological functioning, and adaptive skills. Therapy focuses upon current, problematic relationships and maladaptive patterns of behavior and emotional responses. (See",
"      <a class=\"local\" href=\"#H1193448870\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4043939\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive psychotherapy is used either alone as a primary treatment or as an adjunctive treatment with pharmacotherapy to treat depressed patients with a broad range of functioning. Mild to moderate depression can be treated with supportive psychotherapy alone. Patients with moderate to severe depression, especially moderate to severe suicidal ideation or moderate to severe neurovegetative symptoms (decreased sleep, appetite, and energy), require pharmacotherapy in addition to supportive psychotherapy. (See",
"      <a class=\"local\" href=\"#H1193448877\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial patient assessment consists of the history and mental status examination. The clinician diagnoses the depressive syndrome; identifies any precipitating problems; evaluates the patient&rsquo;s psychosocial functioning, self-esteem, psychological functioning, and adaptive skills; and establishes the patient&rsquo;s goals. Progress is determined by reassessing the patient prior to the beginning of each session with a self-report, standardized, depression rating scale, such as the Patient Health Questionnaire &ndash; Nine Item (PHQ-9) (",
"      <a class=\"graphic graphic_table graphicRef59307 \" href=\"UTD.htm?14/12/14541\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1193448921\">",
"       'Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A conversational approach is used. The clinician is active, answers questions, takes positions, and directs the session to keep the emotional intensity at manageable levels. Anxiety-provoking, prolonged silences are avoided, as are challenging questions that put the patient on the spot. (See",
"      <a class=\"local\" href=\"#H4043939\">",
"       'General treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of specific interventions are used in supportive psychotherapy: praise, reassurance, encouragement, exhortation, structuring the environment, naming the problem, rationalizing, reframing, minimization, clarification, confrontation, interpretation, advice, teaching, anticipatory guidance, and modeling. (See",
"      <a class=\"local\" href=\"#H1193448944\">",
"       'Therapeutic interventions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Research is mixed about the efficacy of supportive psychotherapy as a primary or adjunctive treatment for depression in adults. A number of studies have found that supportive psychotherapy is either similar or inferior to other psychotherapies for treating depression. Limited data suggests that supportive psychotherapy may be comparable to pharmacotherapy for mild to moderate depression. In addition, evidence is mixed as to whether adding supportive psychotherapy to pharmacotherapy improves treatment of depressive syndromes. (See",
"      <a class=\"local\" href=\"#H1193449059\">",
"       'Evidence of efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/1\">",
"      Hellerstein DJ, Rosenthal RN, Pinsker H, et al. A randomized prospective study comparing supportive and dynamic therapies. Outcome and alliance. J Psychother Pract Res 1998; 7:261.",
"     </a>",
"    </li>",
"    <li>",
"     Winston, A. Supportive psychotherapy. In: The American Psychiatric Publishing Textbook of Psychiatry, Fifth Edition, Hales, RE, Yudofsky, SC, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.1257.",
"    </li>",
"    <li>",
"     Buckley, PJ. Applications of individual supportive psychotherapy to psychiatric disorders. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.447.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/4\">",
"      Tanielian TL, Marcus SC, Suarez AP, Pincus HA. Datapoints: Trends in psychiatric practice, 1988-1998: II. Caseload and treatment characteristics. Psychiatr Serv 2001; 52:880.",
"     </a>",
"    </li>",
"    <li>",
"     Winston, A, Rosenthal, RN, Pinsker, H. Introduction to supportive psychotherapy, 1st ed, American Psychiatric Pub., Washington, DC 2004.",
"    </li>",
"    <li>",
"     Hellerstein, DJ, Pinsker, H, Rosenthal, RN, Klee, S. Supportive Therapy as the Treatment Model of Choice. J Psychother Pract Res 1994; 3:300.",
"    </li>",
"    <li>",
"     Pinsker, H. A primer of supportive psychotherapy, Analytic Press, Hillsdale, NJ 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/8\">",
"      Dewald PA. Principles of supportive psychotherapy. Am J Psychother 1994; 48:505.",
"     </a>",
"    </li>",
"    <li>",
"     Hellerstein, DJ. Combining supportive psychotherapy with medication. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/10\">",
"      American Psychiatric Association. Practice Guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry 2010; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition  www.psych.org/guidelines/mdd2010.",
"    </li>",
"    <li>",
"     Depression: the treatment and management of depression in adults (update). www.NICE.org.UK/CG90 (Accessed on October 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/13\">",
"      Parikh SV, Segal ZV, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. J Affect Disord 2009; 117 Suppl 1:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/14\">",
"      Misch DA. Basic strategies of dynamic supportive therapy. J Psychother Pract Res 2000; 9:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/15\">",
"      Douglas CJ. Teaching supportive psychotherapy to psychiatric residents. Am J Psychiatry 2008; 165:445.",
"     </a>",
"    </li>",
"    <li>",
"     Winston, A, Goldstein, M. Theory of supportive psychotherapy. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.393.",
"    </li>",
"    <li>",
"     Rosenthal, RN. Techniques of individual supportive psychotherapy. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC  p.417.",
"    </li>",
"    <li>",
"     Gabbard, GO. Psychodynamic psychiatry in clinical practice, 4th ed, American Psychiatric Pub., Washington, DC 2005.",
"    </li>",
"    <li>",
"     Rockland, LH. Supportive therapy : a psychodynamic approach, Basic Books, New York 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/20\">",
"      Rockland LH. Psychoanalytically oriented supportive therapy: literature review and techniques. J Am Acad Psychoanal 1989; 17:451.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard, GO. Techniques of psychodynamic psychotherapy. In: Textbook of  Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Washington, DC 2009. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/22\">",
"      Cuijpers P, van Straten A, Andersson G, van Oppen P. Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 2008; 76:909.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard, GO. Long-Term Psychodynamic Psychotherapy: a Basic Text, 2nd, American Psychiatric Publishing, Arlington VA 2010.",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006",
"",
" file://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm (Accessed on November 26, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/25\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/26\">",
"      Winston A. Practical psychotherapy: integrated psychotherapy. Psychiatr Serv 2003; 54:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/27\">",
"      Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/28\">",
"      Kroenke, K, Spitzer, RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatric Annals 2002; 32:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/29\">",
"      Zimmerman M, Chelminski I, McGlinchey JB, Posternak MA. A clinically useful depression outcome scale. Compr Psychiatry 2008; 49:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/30\">",
"      Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry 2004; 161:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/31\">",
"      Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/32\">",
"      Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/33\">",
"      Pinsker H. The role of theory in teaching supportive psychotherapy. Am J Psychother 1994; 48:530.",
"     </a>",
"    </li>",
"    <li>",
"     Gabbard, GO, American Psychiatric Publishing. Textbook of psychotherapeutic treatments, 1st ed, American Psychiatric Pub., Washington, DC 2009.",
"    </li>",
"    <li>",
"     Werman, DS. The practice of supportive psychotherapy, Brunner/Mazel, New York 1984.",
"    </li>",
"    <li>",
"     Winston, A, Goldstein, M. Theory of supportive psychotherapy. In: Textbook of Psychotherapeutic Treatments, Gabbard GO (Ed), American Psychiatric Publishing, Washington, DC 2009. p.393.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/37\">",
"      Horvath, AO, Symonds, SB. Relation between working alliance and outcome in psychotherapy: A meta-analysis. J Couns Psychol 1991; 38:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/38\">",
"      Dekker J, Molenaar PJ, Kool S, et al. Dose-effect relations in time-limited combined psycho-pharmacological treatment for depression. Psychol Med 2005; 35:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/39\">",
"      Molenaar PJ, Boom Y, Peen J, et al. Is there a dose-effect relationship between the number of psychotherapy sessions and improvement of social functioning? Br J Clin Psychol 2010.",
"     </a>",
"    </li>",
"    <li>",
"     Herllerstein, DJ. Combining supportive psychotherapy with medication. In: Textbook of Psychotherapeutic Treatments, Gabbard, GO (Eds), American Psychiatric Publishing, Inc., Washington, DC 2009. p.465.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/41\">",
"      de Maat S, Dekker J, Schoevers R, et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety 2008; 25:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/42\">",
"      Ekers D, Richards D, Gilbody S. A meta-analysis of randomized trials of behavioural treatment of depression. Psychol Med 2008; 38:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/43\">",
"      Kocsis JH, Gelenberg AJ, Rothbaum BO, et al. Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. Arch Gen Psychiatry 2009; 66:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/44\">",
"      Cuijpers P, van Straten A, Bohlmeijer E, et al. The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size. Psychol Med 2010; 40:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/45\">",
"      Cuijpers P, Smit F, Bohlmeijer E, et al. Efficacy of cognitive-behavioural therapy and other psychological treatments for adult depression: meta-analytic study of publication bias. Br J Psychiatry 2010; 196:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/46\">",
"      Barber JP, Stratt R, Halperin G, Connolly MB. Supportive techniques: are they found in different therapies? J Psychother Pract Res 2001; 10:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/47\">",
"      Wallerstein RS. The Psychotherapy Research Project of the Menninger Foundation: an overview. J Consult Clin Psychol 1989; 57:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/48\">",
"      Driessen E, Cuijpers P, de Maat SC, et al. The efficacy of short-term psychodynamic psychotherapy for depression: a meta-analysis. Clin Psychol Rev 2010; 30:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/49\">",
"      Simson U, Nawarotzky U, Friese G, et al. Psychotherapy intervention to reduce depressive symptoms in patients with diabetic foot syndrome. Diabet Med 2008; 25:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/50\">",
"      Are&aacute;n PA, Raue P, Mackin RS, et al. Problem-solving therapy and supportive therapy in older adults with major depression and executive dysfunction. Am J Psychiatry 2010; 167:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/51\">",
"      Rosso G, Martini B, Maina G. Brief dynamic therapy and depression severity: A single-blind, randomized study. J Affect Disord 2013; 147:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/52\">",
"      Kool S, Dekker J, Duijsens IJ, et al. Efficacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003; 11:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/53\">",
"      Molenaar PJ, Dekker J, Van R, et al. Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression? Depress Anxiety 2007; 24:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16601/abstract/54\">",
"      Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry 1998; 55:452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14687 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-103.10.120.51-2DFBF20D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16601=[""].join("\n");
var outline_f16_13_16601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1193449145\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448870\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448877\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448891\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448921\">",
"      ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H714936\">",
"      Standardized, self-report rating scale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448928\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4043939\">",
"      General treatment principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1841864\">",
"      Logistics and structure of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193448944\">",
"      Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H980023\">",
"      - Self-esteem",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H980139\">",
"      - Psychological functioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H980147\">",
"      - Adaptive skills",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1193449045\">",
"      - Pharmacotherapy combined with supportive psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193449059\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1193449068\">",
"      Supportive psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12494875\">",
"      - Compared with treatment as usual",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4773619\">",
"      - Compared with other psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17110555\">",
"      - Compared with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3568988\">",
"      Supportive psychotherapy combined with pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6147552\">",
"      - Compared with pharmacotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6147568\">",
"      - Compared with psychotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1193449145\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14687\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14687|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?25/29/26065\" title=\"form 1\">",
"      CUDOS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14687|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/12/14541\" title=\"table 1\">",
"      PHQ-9 questionnaire",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/42/28328?source=related_link\">",
"      Depression in adults: Psychodynamic psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38201?source=related_link\">",
"      Unipolar depression in adults: Prognosis and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/40/4745?source=related_link\">",
"      Using scales to monitor symptoms and treatment of depression (measurement based care)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16602="Comprehensive health care for children in foster care";
var content_f16_13_16602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Comprehensive health care for children in foster care",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Sandra H Jee, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Moira A Szilagyi, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/13/16602/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/13/16602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 23, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents who spend time in foster care have often been exposed to multiple adverse childhood experiences, as have many children whose families are involved with the child welfare system and those living away from their parents in informal placements with relatives.",
"   </p>",
"   <p>",
"    An understanding of the structure, goals, and mandates of the foster care system, as well as the unique health, mental health, developmental, and educational problems of children and adolescents in foster care, facilitates provision of appropriate comprehensive care to this vulnerable population [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive health care for children and adolescents in foster care will be discussed here. The epidemiology of foster care and an overview of the foster care system in the United States are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/51/27448?source=see_link\">",
"     \"Epidemiology of foster care placement and overview of the foster care system in the United States\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEALTH NEEDS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in foster care are a uniquely vulnerable population. They are classified as children with special health care needs by the American Academy of Pediatrics because of the high prevalence of chronic medical, developmental, and mental health problems, most of which predate placement in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Most children in foster care have at least one chronic medical problem (",
"    <a class=\"graphic graphic_table graphicRef57645 \" href=\"UTD.htm?13/27/13755\">",
"     table 1",
"    </a>",
"    ); one-fourth have three or more [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2,4-9\">",
"     2,4-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link\">",
"     \"Children with special health care needs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Throughout this topic, the concept of health encompasses physical (including dental), mental, behavioral, developmental, and educational health. The health problems of children in foster care include, but are not limited to [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2,4-8,10\">",
"     2,4-8,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prematurity",
"     </li>",
"     <li>",
"      Prenatal drug exposure",
"     </li>",
"     <li>",
"      Chronic medical illness",
"     </li>",
"     <li>",
"      Neurologic conditions, genetic and congenital problems",
"     </li>",
"     <li>",
"      Dental problems",
"     </li>",
"     <li>",
"      Hearing and vision impairment",
"     </li>",
"     <li>",
"      Elevated lead levels",
"     </li>",
"     <li>",
"      Exposure to tuberculosis, sexually transmitted infections, and hepatitis",
"     </li>",
"     <li>",
"      Developmental disabilities",
"     </li>",
"     <li>",
"      Psychosocial deprivation",
"     </li>",
"     <li>",
"      Lack of prior health care",
"     </li>",
"     <li>",
"      Under-immunization",
"     </li>",
"     <li>",
"      Educational, behavioral, and mental health problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Complex childhood trauma and toxic stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complex childhood trauma underlies many of the health problems affecting children and adolescents in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/11\">",
"     11",
"    </a>",
"    ]. Understanding the impact of multiple adverse childhood experiences is fundamental to providing appropriate care for these children. Their health problems are compounded by the trauma of removal and separation from their parents and the ongoing uncertainty of living in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2,6,12-15\">",
"     2,6,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complex childhood trauma and the chronic stress that it engenders adversely affect brain development [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/11,16-20\">",
"     11,16-20",
"    </a>",
"    ]. The areas of the brain that are affected are involved in executive function, memory, emotional regulation, attention, and stress reactivity. The impact on cognitive and emotional development manifests as insecure attachment, developmental delays, and significant behavioral and emotional problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/4,11,21\">",
"     4,11,21",
"    </a>",
"    ]. Exposure to early maltreatment can also negatively impact resilience of children [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children in foster care have had multiple adverse experiences by the time they enter foster care. Infants and young children entering foster care have high rates of prenatal substance exposure, prematurity, and chaotic and inappropriate caregiving by impaired parents and other care providers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/6\">",
"     6",
"    </a>",
"    ]. Children entering foster care may have experienced significant levels of interpersonal violence in their families and communities and impaired caregiving in addition to the maltreatment in the form of abuse or neglect that resulted in removal and placement in foster care.",
"   </p>",
"   <p>",
"    Maltreatment is the ultimate breach of the parent-child relationship. Most young children in foster care have experienced ongoing or intermittent neglect of their most basic needs; they also may have been physically or sexually abused. Rigid, harsh discipline by a parent with unrealistic expectations is common in maltreating families, as is the absence of normal predictable nurturance and routines [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mental health issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health is the most significant health concern for children and adolescents in foster care. Behavioral and emotional problems are common [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/1,9,21,24,25\">",
"     1,9,21,24,25",
"    </a>",
"    ]. Primary care providers should be vigilant in monitoring children and adolescents in foster care for past or current mental health problems. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Mental health'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The frequency and severity of emotional problems related to complex childhood trauma are compounded by the child's lack of security and permanence in foster care. More than one-third of children in foster care have moderate to severe emotional problems, and another one-third have less severe disabilities.",
"   </p>",
"   <p>",
"    Behavioral exacerbations may be precipitated by a number of factors, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visitation with birth parents, particularly if it is erratic or causes the child to relive the trauma of separation or rejection.",
"     </li>",
"     <li>",
"      The stress of changes in placement, unrealistic expectations of the foster parents, and court appearances.",
"     </li>",
"     <li>",
"      Changes in caseworkers, childcare providers, or therapists that magnify losses in the lives of these children.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies regarding the emotional health of children in foster care are flawed by small sample size and lack of standardized instruments, criteria for psychopathology, and norms for children in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, the foster parent, social worker, or adolescent self-reports may underestimate emotional or developmental problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/26\">",
"     26",
"    </a>",
"    ]. In a study of children entering foster care in California, for example, 84 percent were found to have emotional or developmental problems during comprehensive assessment, but only 33 percent of foster parents or social workers reported such problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/6\">",
"     6",
"    </a>",
"    ]. In a longitudinal national study, mental health access was low compared with mental health need, but improved as children entered school or had more contact with health providers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/27\">",
"     27",
"    </a>",
"    ]. Disparities in mental health access remain a significant issue for children in foster care, with white children having more access than children of other",
"    <span class=\"nowrap\">",
"     race/ethnicities",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children in foster care account for a disproportionate amount of Medicaid mental health expenditures and are more likely to use Medicaid-reimbursed mental health services than children eligible for Medicaid through Temporary Assistance for Needy Families (TANF, formerly Aid to Families with Dependent Children [AFDC]) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/21,25,29\">",
"     21,25,29",
"    </a>",
"    ]. Children in foster care also are more likely than those in AFDC to have a mental health problem [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/24\">",
"     24",
"    </a>",
"    ]. The mental health symptoms of children in foster care often are manifestations of trauma and can be difficult to distinguish from possible comorbidity.",
"   </p>",
"   <p>",
"    Mental health issues related to early trauma also are prevalent among adolescents in foster care, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 17-year-olds entering foster care in Missouri, 61 percent had at least one psychiatric disorder during their lifetime; 62 percent reported that their earliest psychiatric problem was manifest before entering foster care [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nearly one-third of older adolescents in foster care in the Midwest Study had affective or substance use disorders [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty-five percent of young adults in the Northwest Foster Care Alumni Study had posttraumatic stress disorder (a rate nearly twice that in Vietnam war veterans) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also great concern about the patterns of psychotropic medication use among children and adolescents in foster care. Several studies have demonstrated a high prevalence of use, polypharmacy, prescription of medication for a diagnosis for which the medication is not indicated, and use of two or more drugs from the same class [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/33-37\">",
"     33-37",
"    </a>",
"    ].HYPERLINK",
"   </p>",
"   <p>",
"    The manifestation of emotional disorders related to trauma and toxic stress varies by intensity and frequency of",
"    <span class=\"nowrap\">",
"     stressors/trauma,",
"    </span>",
"    the age, personality, the coping capacities of the child, and the presence or absence of protective factors in the child&rsquo;s life:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants and young children frequently have failure to thrive or sleeping and feeding disorders.",
"     </li>",
"     <li>",
"      Preschool and early school-age children may have problems with toileting, emotional self-regulation, sleep, frequent tantrums, aggression, difficulty with transitions and hyperactivity.",
"     </li>",
"     <li>",
"      Anxiety is more common and depression is less common among children in foster care than expected. Depression may be a later manifestation of early childhood trauma. It may manifest by withdrawal and social isolation or recurrent somatic symptoms that escalate during times of stress or anxiety. Anxiety may manifest as inattention, hyperactivity, high reactivity, or extreme worry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=see_link\">",
"       \"Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some children in foster care have symptoms that meet the criteria for post-traumatic stress disorder with hyper-arousal and high reactivity, re-experiencing (intrusive memories, nightmares about the trauma), and avoidance (memory deficits about trauma, guilt, worry, or numbing).",
"     </li>",
"     <li>",
"      Adolescents may test the limits of acceptable social behavior through truancy, delinquency, substance abuse, sexual experimentation, and self-destructive or violent activities.",
"     </li>",
"     <li>",
"      Early deprivation can lead to reactive attachment disorder, which can have long-lasting implications for interpersonal relationships [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/38\">",
"       38",
"      </a>",
"      ]. Children may view the world as a hostile and unpredictable place and have great difficulty forming healthy attachments to adult caregivers or significant others.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Exposure to violence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Violence exposure among children in foster care was evaluated through interviews of 300 school-aged children from Los Angeles county [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/39\">",
"     39",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eighty-five percent had witnessed violence in their lifetime; of these, 54 percent had witnessed violence in the previous six months",
"     </li>",
"     <li>",
"      Fifty-one percent had been a victim of violence in their lifetime; of these, 41 percent had been victims of violence in the previous six months",
"     </li>",
"     <li>",
"      Children in foster care have also experienced high levels of domestic violence, with a potential lifetime exposure of approximately 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/40\">",
"       40",
"      </a>",
"      ] &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Child abuse and the effects of witnessing violence are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"     \"Evaluation of sexual abuse in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"     \"Child neglect and emotional abuse\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link&amp;anchor=H3#H3\">",
"     \"Childhood exposure to intimate partner violence\", section on 'Effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Development and education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cognitive and academic achievement of children and adolescents in foster care is similar to that of minority children of low socioeconomic status living with their birth families [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/41\">",
"     41",
"    </a>",
"    ]. However, children in foster care have more developmental and educational problems and lower rates of high school completion. Educational problems include learning disabilities, behavior disorders, and limited cognitive ability [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=see_link&amp;anchor=H8#H8\">",
"     \"Specific learning disabilities in children: Clinical features\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth to six years &ndash; More than one-half of the preschool children in foster care have developmental disabilities, particularly communication disorders, poor social-adaptive skills, personal-social delays, and delayed fine-motor skills. Screening for developmental disabilities is discussed below. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Six to 18 years &ndash; Children in foster care are often behind expected grade level in school performance. The poor school achievement of children in foster care is attributed to a variety of factors, including emotional problems, the impact of complex trauma on the developing brain, frequent changes in school placement, school absence, and the chaos of the children's lives before being placed in foster care. Once in foster care, children may be moved out of their school district, and thus need to acclimate to a new environment. Every school placement change results in about a four-month loss in academic skills [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. Nonetheless, school attendance usually improves in foster care. Screening for educational problems is discussed below. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Screening'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEALTH CARE PROVISION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents enter foster care during a time of crisis, most often as the result of neglect or abuse. Many of these children have unknown health histories and have not had continuous preventive primary health care.",
"   </p>",
"   <p>",
"    Health care management is fundamental to ensuring that the complex needs of these children are met. Health care management is ultimately the responsibility of the foster care agency, but requires the expertise of health professionals. Health care management has multiple components, including ensuring that [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      All medical consents are in place",
"     </li>",
"     <li>",
"      Past health history is pursued and obtained (including family history and family mental health history, if possible)",
"     </li>",
"     <li>",
"      Health information is shared with foster parents and professionals involved in the care of the child",
"     </li>",
"     <li>",
"      All necessary and indicated health care, including preventive care and anticipatory guidance, is received by the child in a timely manner",
"     </li>",
"     <li>",
"      Health information is maintained in a useful format and woven into the permanency plan for the child",
"     </li>",
"     <li>",
"      All caregivers and youth receive education about a child&rsquo;s health problems and treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Components",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health care standards published by the",
"    <a class=\"external\" href=\"file://www2.aap.org/fostercare/\">",
"     American Academy of Pediatrics",
"    </a>",
"    (AAP) detail the components of high-quality health care for children and adolescents in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/3\">",
"     3",
"    </a>",
"    ]. Health care for children and adolescents in the foster care system has several major components, discussed below [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Admission health series to identify emerging health needs and monitor the child's transition into and adjustment to foster care. In addition to information gathering, the admission health series includes initial screening (within 72 hours of placement), comprehensive health assessment (within one month of placement), and follow-up visit (30 to 60 days after the comprehensive assessment). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Initial screening'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H16\">",
"       'Comprehensive health assessment'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H27\">",
"       'Follow-up visit'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Developmental or educational evaluation.",
"     </li>",
"     <li>",
"      Mental health evaluation.",
"     </li>",
"     <li>",
"      Dental assessment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the AAP&rsquo;s recommended preventive health care schedule, additional visits may be needed to ensure that all of the child&rsquo;s health, developmental, and mental health care needs are addressed appropriately. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Recommended health surveillance schedule'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A checklist that includes the crucial aspects of the health assessment and health care for children in foster care is available through the",
"    <a class=\"external\" href=\"file://www2.aap.org/fostercare/pdfs/hfca_health_formr.pdf\">",
"     AAP",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Health information gathering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Health information gathering in foster care is an ongoing process. Ideally, the investigating child protective worker or foster care caseworker has a standardized health history form completed by the birth parent. Otherwise, the medical home provider may need to seek health information from previous sources of care (if known), schools, childcare settings, immunization registries, and newborn screening programs.",
"   </p>",
"   <p>",
"    While some have advocated for the use of a medical passport (a portable health record that travels with the child), a standardized, universally accepted health passport has not been developed. Nonetheless, it is helpful to collect the immunization record, medical problem list, medication list, and other pertinent psychosocial information when the child's placement in foster care necessitates a change in the child's health care provider. The medical home can serve as the central repository of health information while the child is in foster care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H16#H16\">",
"     \"Children with special health care needs\", section on 'Medical home'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foster care should be viewed as a window of opportunity for healing for children and adolescents who have experienced complex trauma. Health care for children and adolescents in foster care should [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Be provided in the context of a medical home [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Be well-managed and coordinated",
"     </li>",
"     <li>",
"      Follow the standards of health care for children and adolescents in foster care as set forth by the",
"      <a class=\"external\" href=\"file://www2.aap.org/fostercare/health_care_standard.html\">",
"       AAP and the Child Welfare League of America",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Models of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Models for managing and delivering health services to children in foster care are emerging in response to the multiple and unique needs of this population. The models include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medical home models that specialize in providing primary care services in collaboration with child welfare [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/47\">",
"       47",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evaluation models that provide initial health evaluations upon entrance to foster care and referral to a pediatric medical home [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Preferred provider models in which primary care clinicians receive some extra training and a slightly enhanced fee for caring for a child in foster care [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/49\">",
"       49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Health care management models in which health care coordinators are co-located with child welfare and monitor the care that children receive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these models of health care for children in foster care may not be possible in all areas, certain states and localities have adopted some facets of these programs. Adoption of such models, and compliance with health standards for children and adolescents in foster care, will likely improve health outcomes for this vulnerable and needy population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Medical home model",
"    </span>",
"    &nbsp;&mdash;&nbsp;A foster care medical home is one that provides care that is accessible, comprehensive, compassionate, coordinated, culturally competent, and centered on the child in the context of his or her family relationships and the microculture of foster care. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=see_link&amp;anchor=H16#H16\">",
"     \"Children with special health care needs\", section on 'Medical home'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A collaborative relationship between the medical home and the child welfare system improves communication and health care management, and aids in timely identification of health problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The staff in the medical home should be sensitive to the complex trauma these patients have experienced and knowledgeable regarding the impact of complex trauma on the patients' emotional health and development. Ideally, the medical home should offer trauma-informed on-site mental health services or have a network of mental health providers that is readily accessible. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Complex childhood trauma and toxic stress'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The health of children in foster care often is compromised by inadequate funding, planning, and coordination of services, as well as by poor communication between health and child welfare professionals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Other difficulties in the provision of quality health care for children in foster care include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/10,51\">",
"     10,51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The absence of an organized system of health care",
"     </li>",
"     <li>",
"      The lack of adequate health care coverage for all their health needs",
"     </li>",
"     <li>",
"      The lack of a documented health history provided by the biologic parents or caregiver at entry to foster care",
"     </li>",
"     <li>",
"      The high mobility of the child among foster care placements and into and out of foster care",
"     </li>",
"     <li>",
"      The high turnover rates of case workers and other professionals in the system",
"     </li>",
"     <li>",
"      Lack of health provider knowledge about the impact of trauma on children and its treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    State Medicaid systems rarely adequately reimburse for all the services that these children require, especially mental health services. In general, Medicaid may not pay for services that have been shown to be of benefit to highly traumatized children, such as therapeutic foster care, mentored visitation, and parent-child interactive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/52\">",
"     52",
"    </a>",
"    ]. Some communities have addressed these problems by enrolling Medicaid-eligible children and adolescents in foster care into prepaid capitated health plans (Medicaid managed care) to provide an immediate, organized system for comprehensive care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/53\">",
"     53",
"    </a>",
"    ]. However, mental health care has not always been adequately addressed or covered. Other communities have provided a centralized source of comprehensive care or identified preferred providers who are willing and able to provide the scope of required services by cobbling together a variety of funding streams [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/54\">",
"     54",
"    </a>",
"    ]. Many such programs ensure quality health services but operate at a substantial deficit. Medicaid reform under the Affordable Care Act is anticipated to impact health care services and access for children in foster care. Some states, such as New York, will mandate immediate enrollment of children in foster care into Medicaid Managed Care but are also in the process of defining a package of benefits that would promote integrated care models, preventive mental health services, and appropriate coverage for children with complex medical, mental health,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    developmental health problems.",
"   </p>",
"   <p>",
"    The diffusion of authority and responsibility for the health care of children and adolescents in foster care is particularly challenging. Caseworkers often have limited health information available to them at the time of removal and placement. In addition, they may have insufficient knowledge or training to know what types of information should be collected.",
"   </p>",
"   <p>",
"    Children and adolescents in foster care may have had fragmented or sparse access to health services before placement. Foster parents are typically provided with little past health history and may need to choose the child's health care provider with little guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delays in referrals are common; professionals may wait to see whether the child will remain in foster care before making the referral. Many young children do not receive adequate preventive health care while in placement [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INITIAL SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial screening ideally should occur within 72 hours of removal from the birth parent and placement in a foster or kinship home [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/44,45,55\">",
"     44,45,55",
"    </a>",
"    ]. The birth parent(s) should be encouraged to attend the initial health screening if at all possible. Their attendance may provide the only opportunity for the clinician to obtain a detailed and accurate medical history and family history about the child. However, health screening should not be delayed if the birth parents are unable to attend.",
"   </p>",
"   <p>",
"    The objectives of the initial health screen are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To assess for neglect, physical abuse,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      sexual abuse (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=see_link\">",
"       \"Differential diagnosis of suspected child abuse\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      To screen for contagious diseases (eg, varicella, impetigo, lice, scabies)",
"     </li>",
"     <li>",
"      To identify acute mental health issues",
"     </li>",
"     <li>",
"      To identify acute and chronic health needs in need of immediate attention",
"     </li>",
"     <li>",
"      To ensure that the child has all necessary medications, immunizations, equipment, and referrals",
"     </li>",
"     <li>",
"      To provide guidance regarding the empathetic management of behaviors related to prior trauma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should ensure that the child has any necessary medications or medical equipment and should provide appropriate health education to the new caregiver. The caregiver should receive guidance regarding the impact of complex trauma and removal on children and how to support the child through the transition into foster care (",
"    <a class=\"graphic graphic_table graphicRef61829 \" href=\"UTD.htm?39/29/40412\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     COMPREHENSIVE HEALTH ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive health assessment that includes formal screening for mental health and developmental problems should take place within one month of placement into foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/13,44,45\">",
"     13,44,45",
"    </a>",
"    ]. A checklist that includes the crucial aspects of the health assessment and health care for children in foster care is available through the",
"    <a class=\"external\" href=\"file://www2.aap.org/fostercare/pdfs/hfca_health_formr.pdf\">",
"     American Academy of Pediatrics",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The goals of the comprehensive health assessment are to identify and formulate a management plan for each health problem, and ensure that the health plan is communicated to the child welfare caseworker and foster parent. It is important to see the child privately for at least a few minutes to ensure that the child feels supported and cared for in their placement, and to perform health risk behavior screening (particularly for adolescents). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Health needs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Anticipatory guidance, particularly related to chronic illness and behavioral concerns, may help to avoid unnecessary visits to the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. Referral for mental health, developmental, educational, and dental assessments should be made at this time if not already in process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Foster care history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history for a child in foster care should include information about the child's reason for placement, the child&rsquo;s trauma history, legal status, and the names and roles of the child welfare workers who are responsible for the child (eg, foster parents, caseworker, law guardian). Information should be gathered from as many sources as possible (previous health care providers, caseworker, foster parents, natural parents, other relatives, schools, childcare centers, etc) to obtain as complete medical, family, social, behavioral, and educational histories as possible.",
"   </p>",
"   <p>",
"    The clinician should seek details of the child's current and any past foster care history:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age and circumstances under which the child entered the foster care system, including the psychosocial history (maltreatment history, family composition, family disruption, domestic violence exposure, family mental health history, family involvement with criminal justice, etc)",
"     </li>",
"     <li>",
"      The number of new placements and the",
"      <span class=\"nowrap\">",
"       circumstances/reasons",
"      </span>",
"      for the placement changes",
"     </li>",
"     <li>",
"      The child's feelings about being in foster care",
"     </li>",
"     <li>",
"      The frequency and nature of contact with biologic parents and siblings",
"     </li>",
"     <li>",
"      The composition of the foster family (adults in the home; children in the home whether birth, adopted, or in foster care)",
"     </li>",
"     <li>",
"      How other children in foster care fared in this foster family",
"     </li>",
"     <li>",
"      The foster parents' attitudes and beliefs regarding discipline",
"     </li>",
"     <li>",
"      How the foster parent plans to integrate the child into their family",
"     </li>",
"     <li>",
"      The requirements of any potential reunification plan",
"     </li>",
"     <li>",
"      Whether the child is eligible for adoption",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children placed in foster care should have a comprehensive physical examination to assess their health status. Particular attention should be paid to growth parameters, skin findings, vision, hearing, dental, musculoskeletal, and neurologic assessment. Young children should be screened for developmental problems. Adolescents should be assessed for sexual maturation and fitness for sports participation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=see_link\">",
"     \"The preparticipation sports examination in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Growth &ndash; Assessment of growth is an important component of the physical examination for children in foster care. They may have short stature, undernutrition, or obesity. Poor weight gain may be the first sign of poor care in a foster home.",
"      <br/>",
"      <br/>",
"      Short stature is twice as common among children entering foster care as it is in the general population [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/6,7,13,59\">",
"       6,7,13,59",
"      </a>",
"      ]. This usually reflects malnutrition",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychosocial deprivation that preceded placement (\"psychosocial short stature\") [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/60,61\">",
"       60,61",
"      </a>",
"      ]. In a cohort study, 47 percent of 45 children (18 months to 6 years) showed significant catch-up growth during their first year in placement [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A subgroup of children with psychosocial short stature may have hyperphagic short stature (short stature and growth hormone insufficiency in association with hyperphagia and behavioral symptoms, such as stealing food, gorging and vomiting, and foraging for discarded food) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/62\">",
"       62",
"      </a>",
"      ]. These children have spontaneous recovery of growth-hormone production when stress is removed or reduced.",
"      <br/>",
"      <br/>",
"      Obesity is another form of malnutrition that is seen with increasing frequency at entry into, or emerging shortly after entry into, foster care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=see_link\">",
"       \"Clinical evaluation of the obese child and adolescent\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Skin and musculoskeletal examination &ndash; The skin and musculoskeletal system should be examined for signs of recent or old trauma, bruises, scars, deformities, and limitation of function [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Immunization status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunization status of children entering foster care should be determined, if possible. It may be necessary to piece the immunization history together by obtaining medical records from a variety of sources (including school or day care providers). If the immunization history cannot be documented, the child should be considered susceptible to vaccine-preventable illnesses and immunized appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link\">",
"     \"Standard immunizations for children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Close attention should be paid to manifestations of chronic illness (eg, asthma, eczema), which may not have been appropriately cared for before placement in foster care. Anticipatory guidance should be provided to foster parents and caseworkers to address these needs proactively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Routine screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in foster care may not have received adequate health maintenance and preventive care before foster care placement. In addition, circumstances before placement may increase the risk of iron deficiency anemia, lead poisoning, tuberculosis, and other infectious diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/2\">",
"     2",
"    </a>",
"    ]. Routine screening for these and other conditions, including vision and hearing loss, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H7#H7\">",
"     \"Screening tests in children and adolescents\", section on 'Common screening tests in pediatrics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A few conditions deserve special emphasis in the foster care population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Development &ndash; The clinician should use every preventive health care visit as an opportunity to assess development and ensure that children receive further evaluation as indicated. Developmental screening should occur, even though the information obtained may be somewhat inaccurate because the foster caregiver is still getting to know the child. Screening with a validated instrument may increase the detection of developmental delay [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/63\">",
"       63",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"       \"Developmental and behavioral screening tests in primary care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H9#H9\">",
"       \"Developmental-behavioral surveillance and screening in primary care\", section on 'How to provide evidence-based surveillance and screening'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In addition to screening, referral for a full developmental evaluation is recommended unless it is already in process or the child already has an individualized education plan (IEP). In the United States, children younger than three years of age with documented child neglect or abuse are eligible for an Early Intervention evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hearing and speech &ndash; Hearing and speech evaluations may be helpful in identifying toddlers and preschool children who need additional services [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/65\">",
"       65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"       \"Evaluation of hearing impairment in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Education &ndash; Clinicians should ask about school problems and school performance, and request an educational evaluation if school performance is below grade level. Child welfare is mandated by law to maintain children in their school of origin whenever possible, even if they have to provide transportation to do so [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/66\">",
"       66",
"      </a>",
"      ]. However, extraordinary travel requirements may qualify as a compelling reason for a child to change schools upon entry to foster care. Communication between the foster parents, school personnel, the caseworker, and the clinician are essential to the identification and amelioration of school issues. School personnel may need help in understanding the child&rsquo;s behavioral issues in the context of his or her history of trauma and loss. The comprehensive evaluation and management of children with developmental and educational disorders requires an organized system of follow-up and consultation [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Dental health &ndash; Children older than 12 months should be referred to a dentist for an initial dental assessment and children should receive routine dental care while in foster care. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=see_link\">",
"       \"Preventive dental care and counseling for infants and young children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal lifestyles may increase the risk of vertically transmitted infections such as syphilis, herpes simplex virus, human immunodeficiency virus (HIV), and hepatitis B and C among children entering foster care. Adolescents may be at risk for these infections because of unsafe sexual practices, tattoos, or body piercing, or drug use. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The guidelines for testing children and adolescents in foster care for these conditions vary from state to state. However, at entry into foster care, laboratory testing for hepatitis B and C, syphilis, and HIV is recommended. They should be immunized against hepatitis B if they are not immune [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine screening of urine for sexually transmitted infections is recommended for adolescents beginning at age 11 years. Urine pregnancy screening is also recommended for all adolescent females in foster care beginning at age 11 to 12 years.",
"   </p>",
"   <p>",
"    Pediatric providers should become familiar with the particular emancipated minor laws and regulations governing HIV risk assessment, screening, and information sharing for the foster care population in their state [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/67\">",
"     67",
"    </a>",
"    ]. As a general rule, birth parents retain the right to consent for HIV testing unless the child is eligible for adoption or parental rights have been terminated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/67\">",
"     67",
"    </a>",
"    ]. However, adolescents in the foster care system may consent to HIV testing unless they are cognitively impaired. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=see_link&amp;anchor=H17#H17\">",
"     \"Consent in adolescent health care\", section on 'Sexually transmitted infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Mental health",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mental health is the most significant health concern for children and adolescents in foster care. Screening for mental health problems with a validated mental health instrument should be performed during the comprehensive assessment. Information should be obtained from the foster care parent, the child or adolescent in foster care, and the birth parent (if possible) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/26\">",
"     26",
"    </a>",
"    ]. The use of a validated screening instrument (eg, the Strengths and Difficulties Questionnaire: Social-Emotional, the Child Behavior Checklist, the Strengths and Difficulties Questionnaire, etc) can facilitate detection of social-emotional problems [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/68\">",
"     68",
"    </a>",
"    ]. In addition, the child should be referred for a full mental health evaluation if one is not already in process [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/1,14,15,21,24,29,69\">",
"     1,14,15,21,24,29,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Violence exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Child abuse and neglect may occur in foster homes [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/39\">",
"     39",
"    </a>",
"    ]. This possibility should be considered whenever a child is losing or failing to gain appropriate weight in a foster home, if the child's behavior deteriorates, or the child appears depressed or hypervigilant in the presence of the foster parent. It is important to see the child privately, at least for a few minutes, to ensure that he or she feels supported and cared for in the foster care home. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=see_link&amp;anchor=H6#H6\">",
"     \"Poor weight gain in children older than two years of age\", section on 'Limited or inappropriate intake'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=see_link&amp;anchor=H11#H11\">",
"     \"Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children in foster care also should be screened for exposure to violence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=see_link&amp;anchor=H14#H14\">",
"     \"Childhood exposure to intimate partner violence\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Education and support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticipatory guidance, particularly related to chronic illness and behavioral concerns, may help to avoid unnecessary visits to the emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/51,58\">",
"     51,58",
"    </a>",
"    ]. Behavior-shaping techniques should focus on spending time in with the child, using positive words and instructions, distraction techniques, teachable moments, and rewarding positive behaviors. Health care professionals should inform foster parents that children may experience emotional difficulties during the transitional period into foster care; providing consistency and support in the foster home environment may help with this adjustment. School-age children and adolescents need extensive education about healthy relationships, conflicted loyalties, reproductive health, safe sexual practices, handling their emotions, identity formation, identifying positive adult mentors, and the benefits of mental health therapy. Information about effective interventions and parenting the traumatized child is available through the",
"    <a class=\"external\" href=\"file://www.nctsn.org/\">",
"     National Child Traumatic Stress Network",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://www.cebc4cw.org/search/topic-areas/\">",
"     California Evidence-Based Clearinghouse for Child Welfare",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     FOLLOW-UP VISIT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The follow-up visit is the final visit in the admission health series. It should occur 30 to 60 days after the comprehensive assessment. The goals of the follow-up visit are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Review of any newly obtained health history",
"     </li>",
"     <li>",
"      Assessment of adjustment to foster care and life in the foster home",
"     </li>",
"     <li>",
"      Assessment of how visitation is going",
"     </li>",
"     <li>",
"      Monitoring for abuse and neglect",
"     </li>",
"     <li>",
"      Provision of support and guidance to the foster parent regarding behavior, discipline, and nurturing the child through the transition process",
"     </li>",
"     <li>",
"      Ongoing health, mental health, and parenting education",
"     </li>",
"     <li>",
"      Completion of immunization series",
"     </li>",
"     <li>",
"      Follow-up care for chronic medical issues",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Questions that help to assess adjustment to foster care include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/70\">",
"     70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    For the foster parent:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"How do you think your child is doing? How does",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      fit into your family?\"",
"     </li>",
"     <li>",
"      \"Does",
"      <span class=\"nowrap\">",
"       s/he",
"      </span>",
"      have any behaviors that you are worried about?\"",
"     </li>",
"     <li>",
"      \"What has it been like for you and others in your home since the child moved in?\"",
"     </li>",
"     <li>",
"      \"Have there been any other significant changes in your family?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the child, without the foster caregiver present (depending upon the child's maturity and ability to communicate):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      \"What is it like for you living in the new home?\"",
"     </li>",
"     <li>",
"      \"What do you like most? What do you like least?\"",
"     </li>",
"     <li>",
"      \"How do you get along with the people in your new home?\"",
"     </li>",
"     <li>",
"      \"What would you like to change?\"",
"     </li>",
"     <li>",
"      \"Do you feel supported in your new home?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to measurement of growth parameters and a brief physical examination, the clinician should review the results of the mental health evaluation and developmental or educational evaluations with the foster parent and birth parent (if available). Adolescents in foster care may be included in these discussions. Standardized assessment tools can be used at follow-up visits to assess for the emergence of new-onset behavioral or developmental difficulties (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link&amp;anchor=H7#H7\">",
"     \"Developmental and behavioral screening tests in primary care\", section on 'Behavioral screening tests'",
"    </a>",
"    ). The clinician should update the health care plan, schedule the next health visit, and communicate with the child's caseworker.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     RECOMMENDED HEALTH SURVEILLANCE SCHEDULE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents in foster care should receive preventive health care services according to the American Academy of Pediatrics&rsquo; (AAP) recommended preventive health care schedule, but may need additional visits for a number of reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/45,71\">",
"     45,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They have a high rate of health and mental health and developmental problems (",
"      <a class=\"graphic graphic_table graphicRef57645 \" href=\"UTD.htm?13/27/13755\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      They live in circumstances that do not meet their needs for stability and permanency",
"     </li>",
"     <li>",
"      They are exposed to multiple transitions and other factors that threaten their health and well-being",
"     </li>",
"     <li>",
"      Children who receive primary and preventive services have improvements in health, development, and educational measures while in foster care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the AAP recommends that children in foster care have more frequent health care visits to monitor their physical, emotional, developmental, and mental health:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants should be seen monthly until age six months, particularly if born prematurely",
"     </li>",
"     <li>",
"      Toddlers should have an extra visit at age 21 months focusing on development",
"     </li>",
"     <li>",
"      Every child in foster care should be seen every six months between ages 24 months and 21 years to monitor health, mental health, behavioral and",
"      <span class=\"nowrap\">",
"       developmental/educational",
"      </span>",
"      progress and to provide appropriate support and education",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One challenge is receiving financial reimbursement for adhering to this proactive health visit schedule.",
"   </p>",
"   <p>",
"    During preventive health care visits, the clinician should:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide ongoing support and guidance to foster parents regarding discipline and managing behaviors in the context of a child's trauma history and developmental stage.",
"     </li>",
"     <li>",
"      Screen for emerging mental health, developmental, and educational issues. If the child younger than six years is not involved in ongoing developmental services, the clinician should use an age-appropriate validated developmental screening instrument to periodically screen for emerging developmental problems. The maximum recommended interval between screenings is six months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"       \"Developmental and behavioral screening tests in primary care\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"       \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If the child is not involved in ongoing mental health services, the clinician should address mental health, emotional, and behavioral issues at the time of each",
"      <span class=\"nowrap\">",
"       preventive/monitoring",
"      </span>",
"      health visit or whenever the foster parent, birth parent, caseworker, teacher, or other professional involved with the child has a concern. Referral to a pediatric mental health professional is indicated when concerns are raised if integrated mental health services are not available in the medical home.",
"     </li>",
"     <li>",
"      Be alert to signs of abuse and neglect. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=see_link\">",
"       \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=see_link\">",
"       \"Evaluation of sexual abuse in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=see_link\">",
"       \"Child neglect and emotional abuse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ensure that all of the child's health needs are appropriately addressed.",
"     </li>",
"     <li>",
"      Focus on the child's assets and strengths.",
"     </li>",
"     <li>",
"      Promote involvement in normalizing activities and healthy lifestyles.",
"     </li>",
"     <li>",
"      Ensure that adolescents are screened for sexually transmitted infections, pregnancy, and high-risk behaviors. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=see_link&amp;anchor=H4#H4\">",
"       \"Guidelines for adolescent preventive services\", section on 'Screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Include anticipatory guidance regarding issues related to foster care: support around visitation, permanency planning, and court-related issues; dealing with conflict between birth and foster parents; and managing behavior in a child with a history of complex trauma. Parents and health care professionals may seek additional resources to address these issues from professional organizations (",
"      <a class=\"graphic graphic_table graphicRef61829 \" href=\"UTD.htm?39/29/40412\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PRIMARY CARE PROVIDER'S ROLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary care provider has an opportunity to be health care provider, health educator, health coordinator, and health advocate for the child in foster care. The provider may be one of the few sources of stability, support, and advice in the child's otherwise chaotic life.",
"   </p>",
"   <p>",
"    The health and development of children in foster care may improve during placement if coordinated, comprehensive, specialized care is provided [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/13,71,72\">",
"     13,71,72",
"    </a>",
"    ]. Pediatric practices that provide medical care for children in foster care should be organized to accommodate the special needs of these children.",
"   </p>",
"   <p>",
"    Specific recommendations for optimizing primary care visits for foster care children include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appointment length should be modified to permit time for comprehensive evaluation and patient education, particularly regarding anticipatory guidance around foster-care-related issues, behavior management, the management of chronic illness, and adolescent issues.",
"     </li>",
"     <li>",
"      The child's physical, emotional, and educational problems must be recognized, considered in the context of his or her life circumstances, and promptly addressed to maximize the child's future development.",
"     </li>",
"     <li>",
"      Mental health services should be provided by a pediatric mental health professional with expertise on complex childhood trauma, if possible.",
"     </li>",
"     <li>",
"      Arrangements should be made for children who need subspecialty care to be seen promptly, and the recommendations of the specialist should be integrated into the primary provider's care plan.",
"     </li>",
"     <li>",
"      Appropriate medical assessment or intervention should not be delayed pending planned reunification with birth parents, because these plans are often disrupted or delayed.",
"     </li>",
"     <li>",
"      Records should be maintained carefully since they are likely to be requested by subsequent providers, child welfare agencies, or the judicial system.",
"     </li>",
"     <li>",
"      An abbreviated health record (\"health passport\") that is updated (particularly regarding health problems, allergies, immunizations, growth curves, and current medications) at each health care encounter should be provided to the foster parent. The \"passport\" should be transferred to the birth, adoptive, or next foster parent(s) at the time of transition. Youth who age out of foster care should receive a copy of their health passport. A secure but accessible web-based health passport is ideal.",
"     </li>",
"     <li>",
"      The clinician should be prepared to lobby on behalf of the child in situations of conflict with or between social service agencies, schools, the parents, and the courts. If necessary, clinicians will need to discuss the child's care with the Guardian ad Litem (law guardian) to assist in decision making regarding the child or adolescent [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/51/27448?source=see_link&amp;anchor=H12#H12\">",
"       \"Epidemiology of foster care placement and overview of the foster care system in the United States\", section on 'Foster care personnel'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The clinician should provide education to the caseworker and other adults who share responsibility for the child's welfare to ensure that health decisions are consistently made in the child's best interest.",
"     </li>",
"     <li>",
"      Clinicians are encouraged to learn about the health needs of youth aging out of the foster care system and to be aware of state (or other local) programs to provide health care coverage for these youth [",
"      <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/74\">",
"       74",
"      </a>",
"      ]. Resources are available through the",
"      <a class=\"external\" href=\"file://www2.aap.org/fostercare/\">",
"       American Academy of Pediatrics",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, pediatric health care providers may wish to participate in aspects of foster care at the community level. They may help to identify and recruit foster parents, participate in continuing education programs for the staff of child welfare agencies or foster parents, share in the development of policies and procedures for health care for children in foster care, or become a member of a citizens' review board that monitors the planning of agencies on behalf of the children in their care. Pediatric health providers may also wish to work at the state level through their local AAP chapter. States are required to engage pediatricians in the development of health care systems for children in foster care [",
"    <a class=\"abstract\" href=\"UTD.htm?16/13/16602/abstract/66\">",
"     66",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children in foster care are a uniquely vulnerable population, with an increased prevalence of chronic medical, developmental, and mental health problems (",
"      <a class=\"graphic graphic_table graphicRef57645 \" href=\"UTD.htm?13/27/13755\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complex childhood trauma underlies many of the health problems affecting children and adolescents in foster care. Their health problems are compounded by the trauma of removal and separation from their parents and the ongoing uncertainty of living in foster care. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Complex childhood trauma and toxic stress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care for children and adolescents in the foster care system includes information gathering, an admission health series consisting of at least three visits, developmental or educational evaluation, mental health evaluation, and a proactive preventive health care schedule. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Health care provision'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial health screening should occur within 72 hours of removal from the birth parent. The objectives include assessment for abuse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neglect, contagious diseases, acute mental health issues, and acute or chronic health needs requiring immediate attention. In addition, this is an opportunity to provide guidance regarding the empathetic management of behaviors related to prior trauma. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Initial screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The comprehensive health assessment should occur within one month of placement. The goals of the comprehensive assessment are to identify and formulate a management plan for each health problem and ensure that the plan is communicated to the child welfare caseworker and foster parent. Referral for mental health, developmental, educational, and dental assessments should be made if not already in process. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Comprehensive health assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The follow-up visit should occur 30 to 60 days after the comprehensive assessment. The follow-up visit provides an opportunity to review newly obtained health history, including the results of the mental health and developmental (or educational) evaluations, assess adjustment to foster care and visitation, monitor for abuse and neglect, and provide support and guidance to the foster parent. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Follow-up visit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children in foster care should receive preventive health services according to the American Academy of Pediatrics&rsquo; schedule for children in foster care. This includes additional visits according to the following schedule: monthly until age six months; every three months from age 6 to 24 months; and every six months from 24 months to 21 years. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Recommended health surveillance schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pediatric practices providing medical care for children in foster care should be organized to accommodate the special needs of these children. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Primary care provider's role'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/1\">",
"      Mather M. Adoption: a forgotten paediatric speciality. Arch Dis Child 1999; 81:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/2\">",
"      Szilagyi M. The pediatric role in the care of children in foster and kinship care. Pediatr Rev 2012; 33:496.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Fostering Health: Health Care for Children and Adolescents in Foster Care, 2nd Edition. Available at www2.aap.org/fostercare/FosteringHealth.html (Accessed on December 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/4\">",
"      Ringeisen H, Casanueva C, Urato M, Cross T. Special health care needs among children in the child welfare system. Pediatrics 2008; 122:e232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/5\">",
"      Simms MD. The foster care clinic: a community program to identify treatment needs of children in foster care. J Dev Behav Pediatr 1989; 10:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/6\">",
"      Halfon N, Mendonca A, Berkowitz G. Health status of children in foster care. The experience of the Center for the Vulnerable Child. Arch Pediatr Adolesc Med 1995; 149:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/7\">",
"      Chernoff R, Combs-Orme T, Risley-Curtiss C, Heisler A. Assessing the health status of children entering foster care. Pediatrics 1994; 93:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/8\">",
"      Jee SH, Barth RP, Szilagyi MA, et al. Factors associated with chronic conditions among children in foster care. J Health Care Poor Underserved 2006; 17:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/9\">",
"      Steele JS, Buchi KF. Medical and mental health of children entering the utah foster care system. Pediatrics 2008; 122:e703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/10\">",
"      Special considerations for the health supervision of children and youth in foster care. Paediatr Child Health 2008; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/11\">",
"      Johnson SB, Riley AW, Granger DA, Riis J. The science of early life toxic stress for pediatric practice and advocacy. Pediatrics 2013; 131:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/12\">",
"      Rosenfeld AA, Pilowsky DJ, Fine P, et al. Foster care: an update. J Am Acad Child Adolesc Psychiatry 1997; 36:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/13\">",
"      Simms MD. Foster children and the foster care system, Part II: Impact on the child. Curr Probl Pediatr 1991; 21:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/14\">",
"      McMillen JC, Zima BT, Scott LD Jr, et al. Prevalence of psychiatric disorders among older youths in the foster care system. J Am Acad Child Adolesc Psychiatry 2005; 44:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/15\">",
"      Pilowsky DJ, Wu LT. Psychiatric symptoms and substance use disorders in a nationally representative sample of American adolescents involved with foster care. J Adolesc Health 2006; 38:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/16\">",
"      McEwen BS. The neurobiology of stress: from serendipity to clinical relevance. Brain Res 2000; 886:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/17\">",
"      Gunnar MR, Fisher PA, Early Experience, Stress, and Prevention Network. Bringing basic research on early experience and stress neurobiology to bear on preventive interventions for neglected and maltreated children. Dev Psychopathol 2006; 18:651.",
"     </a>",
"    </li>",
"    <li>",
"     Center on the Developing Child at Harvard University. Toxic stress: The facts. Available at: developingchild.harvard.edu/topics/science_of_early_childhood/toxic_stress_response/ (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/19\">",
"      Garner AS, Shonkoff JP, Committee on Psychosocial Aspects of Child and Family Health, et al. Early childhood adversity, toxic stress, and the role of the pediatrician: translating developmental science into lifelong health. Pediatrics 2012; 129:e224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/20\">",
"      Shonkoff JP, Garner AS, Committee on Psychosocial Aspects of Child and Family Health, et al. The lifelong effects of early childhood adversity and toxic stress. Pediatrics 2012; 129:e232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/21\">",
"      Halfon N, Berkowitz G, Klee L. Mental health service utilization by children in foster care in California. Pediatrics 1992; 89:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/22\">",
"      Cicchetti D, Rogosh FA, Lynch M, Holt KD. Resilience in maltreated children-processes leading to adaptive outcome. Dev Psychopathol 1993; 5:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/23\">",
"      Cicchetti D, Toth SL. A developmental psychopathology perspective on child abuse and neglect. J Am Acad Child Adolesc Psychiatry 1995; 34:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/24\">",
"      Harman JS, Childs GE, Kelleher KJ. Mental health care utilization and expenditures by children in foster care. Arch Pediatr Adolesc Med 2000; 154:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/25\">",
"      Takayama JI, Bergman AB, Connell FA. Children in foster care in the state of Washington. Health care utilization and expenditures. JAMA 1994; 271:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/26\">",
"      Jee SH, Szilagyi M, Conn AM, et al. Validating office-based screening for psychosocial strengths and difficulties among youths in foster care. Pediatrics 2011; 127:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/27\">",
"      Horwitz SM, Hurlburt MS, Goldhaber-Fiebert JD, et al. Mental health services use by children investigated by child welfare agencies. Pediatrics 2012; 130:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/28\">",
"      Gudi&ntilde;o OG, Martinez JI, Lau AS. Mental health service use by youths in contact with child welfare: racial disparities by problem type. Psychiatr Serv 2012; 63:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/29\">",
"      dosReis S, Zito JM, Safer DJ, Soeken KL. Mental health services for youths in foster care and disabled youths. Am J Public Health 2001; 91:1094.",
"     </a>",
"    </li>",
"    <li>",
"     Courtney, ME, Dworsky, A, Cusick, GR, et al. Midwest evaluation of the adult functioning of former foster youth. Outcomes at age 19: executive summary. www.chapinhall.org/sites/default/files/ChapinHallDocument_3.pdf (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     Pecora PJ, Kessler RC, Williams J, et al. Improving family foster care: Findings from the Northwest Foster Care Alumni Study. Casey Family Programs, Seattle WA, 2005.",
"    </li>",
"    <li>",
"     Kulka RA, Fairbank JA, Jordan K, Weiss D. Trauma and the Vietnam War Generation: Report of Findings from the National Vietnam Veterans Readjustment Study, Routledge, New York 1990.",
"    </li>",
"    <li>",
"     Texas Health and Human Services Commission, 2006. Use of psychoactive medication in Texas foster children, state fiscal year 2005. Available at: www.hhs.state.tx.us/news/release/Analysis.062306.pdf (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/34\">",
"      Zima BT, Bussing R, Crecelius GM, et al. Psychotropic medication treatment patterns among school-aged children in foster care. J Child Adolesc Psychopharmacol 1999; 9:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/35\">",
"      dosReis S, Zito JM, Safer DJ, et al. Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 2005; 15:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/36\">",
"      Zito JM, Safer DJ, Sai D, et al. Psychotropic medication patterns among youth in foster care. Pediatrics 2008; 121:e157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/37\">",
"      Linares LO, Martinez-Martin N, Castellanos FX. Stimulant and atypical antipsychotic medications for children placed in foster homes. PLoS One 2013; 8:e54152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/38\">",
"      Minnis H, Everett K, Pelosi AJ, et al. Children in foster care: mental health, service use and costs. Eur Child Adolesc Psychiatry 2006; 15:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/39\">",
"      Stein BD, Zima BT, Elliott MN, et al. Violence exposure among school-age children in foster care: relationship to distress symptoms. J Am Acad Child Adolesc Psychiatry 2001; 40:588.",
"     </a>",
"    </li>",
"    <li>",
"     National Survey of Child and Adolescent Well-Being (NSCAW). One year in foster care. Wave 1 Data Analysis Report www.acf.hhs.gov/sites/default/files/opre/oyfc_report.pdf (Accessed on December 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/41\">",
"      Schor EL. Foster care. Pediatr Rev 1989; 10:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/42\">",
"      Wood D, Halfon N, Scarlata D, et al. Impact of family relocation on children's growth, development, school function, and behavior. JAMA 1993; 270:1334.",
"     </a>",
"    </li>",
"    <li>",
"     Kerbow D.  Patterns of urban student mobility and local school reform. Technical Report No. 5. Center for Research on the Education of Children Placed at Risk, Washington, DC 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/44\">",
"      American Academy of Pediatrics Committee on Early Childhood, Adoption, and Dependent Care: Health care of children in foster care. Pediatrics 1994; 93:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/45\">",
"      Committee on Early Childhood, Adoption, and Dependent Care, American Academy of Pediatarics. Health care of young children in foster care. Pediatrics 2002; 109:536.",
"     </a>",
"    </li>",
"    <li>",
"     National Center for Medical Home Implementation. Available at: www.medicalhomeinfo.org (Accessed on December 13, 2012).",
"    </li>",
"    <li>",
"     Szilagyi MA. The foster care medical home. Future of Pediatrics Conference, Orlando, FL, July 2007.",
"    </li>",
"    <li>",
"     FaCES Clinic. UMass Memorial Medical Center file://www.umassmemorial.org/support-groups-and-education/health-articles/faces-foster-care-health-services-clinic-3906 (Accessed on October 12, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/49\">",
"      Jaudes PK, Bilaver LA, Goerge RM, et al. Improving access to health care for foster children: the Illinois model. Child Welfare 2004; 83:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/50\">",
"      Jee SH, Szilagyi MA, Blatt SD, et al. Timely identification of mental health problems in two foster care medical homes. Child Youth Serv Rev 2010; 32:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/51\">",
"      Rubin DM, Alessandrini EA, Feudtner C, et al. Placement changes and emergency department visits in the first year of foster care. Pediatrics 2004; 114:e354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/52\">",
"      Fisher PA, Burraston B, Pears K. The early intervention foster care program: permanent placement outcomes from a randomized trial. Child Maltreat 2005; 10:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/53\">",
"      Schor EL, Neff JM, LaAsmar JL. The Chesapeake Health Plan: an HMO model for foster children. Child Welfare 1984; 63:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/54\">",
"      Mushlin MB, Levitt L, Anderson L. Court-ordered foster family care reform: a case study. Child Welfare 1986; 65:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/55\">",
"      Schor EL. Foster care. Pediatr Clin North Am 1988; 35:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/56\">",
"      Halfon N, Klee L. Health services for California's foster children: current practices and policy recommendations. Pediatrics 1987; 80:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/57\">",
"      Flaherty EG, Weiss H. Medical evaluation of abused and neglected children. Am J Dis Child 1990; 144:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/58\">",
"      Jee SH, Antonucci TC, Aida M, et al. Emergency department utilization by children in foster care. Ambul Pediatr 2005; 5:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/59\">",
"      Wyatt DT, Simms MD, Horwitz SM. Widespread growth retardation and variable growth recovery in foster children in the first year after initial placement. Arch Pediatr Adolesc Med 1997; 151:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/60\">",
"      Powell GF, Brasel JA, Raiti S, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. II. Endocrinologic evaluation of the syndrome. N Engl J Med 1967; 276:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/61\">",
"      Powell GF, Brasel JA, Blizzard RM. Emotional deprivation and growth retardation simulating idiopathic hypopituitarism. I. Clinical evaluation of the syndrome. N Engl J Med 1967; 276:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/62\">",
"      Skuse D, Albanese A, Stanhope R, et al. A new stress-related syndrome of growth failure and hyperphagia in children, associated with reversibility of growth-hormone insufficiency. Lancet 1996; 348:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/63\">",
"      Jee SH, Szilagyi M, Ovenshire C, et al. Improved detection of developmental delays among young children in foster care. Pediatrics 2010; 125:282.",
"     </a>",
"    </li>",
"    <li>",
"     The Child Abuse Prevention and Treatment Act. (P.L. 93-247). Amended and re-authorized on June 25, 2003, by the Keeping Children and Families Safe Act of 2003. (P.L. 108-36).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/65\">",
"      American Academy of Pediatrics. Committee on Early Childhood and Adoption and Dependent Care. Developmental issues for young children in foster care. Pediatrics 2000; 106:1145.",
"     </a>",
"    </li>",
"    <li>",
"     Public Law 110-351. Fostering Connections to Success and Increasing Adoptions Act of 2008. file://www.fosteringconnections.org/tools/assets/files/Public_Law_110-351.pdf (Accessed on December 14, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/67\">",
"      Szilagyi M. The pediatrician and the child in foster care. Pediatr Rev 1998; 19:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/68\">",
"      Jee SH, Halterman JS, Szilagyi M, et al. Use of a brief standardized screening instrument in a primary care setting to enhance detection of social-emotional problems among youth in foster care. Acad Pediatr 2011; 11:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/69\">",
"      Williams J, Jackson S, Maddocks A, et al. Case-control study of the health of those looked after by local authorities. Arch Dis Child 2001; 85:280.",
"     </a>",
"    </li>",
"    <li>",
"     Szilagyi, M. Foster Care. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn, M, Zuckerman, B, Caronna, EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.450.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/71\">",
"      Jee SH, Simms MD. Health and well-being of children in foster care placement. Pediatr Rev 2006; 27:34.",
"     </a>",
"    </li>",
"    <li>",
"     White R, Benedict M. Health Status and Utilization Patterns of Children in Foster Care: Executive Summary. Administration for Children, Youth and Families. US Department of Health and Human Services Grant #90-PD-86509, 1986.",
"    </li>",
"    <li>",
"     Heartz R. Guardians ad litem in child abuse and neglect proceedings: Clarifying the roles to improve effectiveness. CASAnet Resources. Available at: casanet.org/library/guardian-ad-litem/gal-e-section3.htm (Accessed on September 10, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/13/16602/abstract/74\">",
"      Council On Foster Care, Adoption, And Kinship Care And Committee On Early Childhood. Health care of youth aging out of foster care. Pediatrics 2012; 130:1170.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 588 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16602=[""].join("\n");
var outline_f16_13_16602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEALTH NEEDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Complex childhood trauma and toxic stress",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mental health issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Exposure to violence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Development and education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEALTH CARE PROVISION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Health information gathering",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Models of delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Medical home model",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Barriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INITIAL SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      COMPREHENSIVE HEALTH ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Foster care history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Immunization status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Routine screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Mental health",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Violence exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Education and support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      FOLLOW-UP VISIT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      RECOMMENDED HEALTH SURVEILLANCE SCHEDULE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PRIMARY CARE PROVIDER'S ROLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/588\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/588|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/27/13755\" title=\"table 1\">",
"      Health problems foster care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/29/40412\" title=\"table 2\">",
"      Foster care resources",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18408?source=related_link\">",
"      Child neglect and emotional abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31097?source=related_link\">",
"      Childhood exposure to intimate partner violence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/5/27737?source=related_link\">",
"      Children with special health care needs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8378?source=related_link\">",
"      Clinical evaluation of the obese child and adolescent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/24/5512?source=related_link\">",
"      Consent in adolescent health care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/10/5289?source=related_link\">",
"      Depression in adolescents: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23990?source=related_link\">",
"      Differential diagnosis of suspected child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/51/27448?source=related_link\">",
"      Epidemiology of foster care placement and overview of the foster care system in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/12/14538?source=related_link\">",
"      Etiology and evaluation of failure to thrive (undernutrition) in children younger than two years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35258?source=related_link\">",
"      Evaluation of sexual abuse in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19000?source=related_link\">",
"      Guidelines for adolescent preventive services",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/21/38233?source=related_link\">",
"      Poor weight gain in children older than two years of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/26/33192?source=related_link\">",
"      Preventive dental care and counseling for infants and young children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32665?source=related_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/13/36058?source=related_link\">",
"      The preparticipation sports examination in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_13_16603="Histologic features UIP";
var content_f16_13_16603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic features of usual interstitial pneumonia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Key histologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dense fibrosis causing remodeling of lung architecture with frequent \"honycomb\" fibrosis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fibroblastic foci typically scattered at the edges of dense scars.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patchy lung involvement.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frequent subpleural and paraseptal distribution.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pertinent negative findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of active lesions of other interstitial diseases (ie, sarcoidosis or Langerhans cell histiocytosis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of marked interstitial chronic inflammation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomas: inconspicuous or absent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of substantial inorganic dust deposits, ie, asbestos bodies (except for carbon black pigment).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lack of marked eosinophilia.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16603=[""].join("\n");
var outline_f16_13_16603=null;
var title_f16_13_16604="Preparation of rectal formulations of thionamides";
var content_f16_13_16604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preparation of rectal formulations of thionamides",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Methimazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suppository",
"       </td>",
"       <td>",
"        Dissolve 1200 mg methimazole in 12 mL of water and add to 52 mL cocoa butter containing two drops of polysorbate (Span) 80. Stir mixture to form an emulsion and pour into 2.6 mL suppository molds to cool.",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Propylthiouracil",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Suppository",
"       </td>",
"       <td>",
"        Dissolve 200 mg of propylthiouracil in a polyethylene glycol base and put into suppository tablets",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Retention enema",
"       </td>",
"       <td>",
"        <p>",
"         Dissolve eight to twelve 50 mg tablets of propylthiouracil in 90 mL of sterile water",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"        <p>",
"         Dissolve eight 50 mg tablets of propylthiouracil in 60 mL of mineral oil enema (eg, Fleet mineral oil) or in 60 mL of sodium phosphates enema solution* (eg, Fleet enema phospho soda)",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"        <p>",
"         For either enema preparation: Administer by Foley catheter inserted into the rectum, with balloon inflated to prevent leakage for two hour retention",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Additional information on preparation described in:",
"    <br>",
"     <br>",
"      <ul>",
"       <li>",
"        Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am 2006; 35:663.",
"       </li>",
"       <li>",
"        Yeung SC, Go R, Balasubramanyam A. Rectal administration of iodide and propylthiouracil in the treatment of thyroid storm. Thyroid 1995; 5:403.",
"       </li>",
"       <li>",
"        Jongjaroenprasert W, Akarawut W, Chantasart D, et al. Rectal administration of propylthiouracil in hyperthyroid patients: comparison of suspension enema and suppository form. Thyroid 2002; 12:627.",
"       </li>",
"      </ul>",
"      <div class=\"footnotes\">",
"       * Avoid phosphate containing rectal preparations in patients with renal insufficiency or heart failure.",
"      </div>",
"      <div class=\"reference\">",
"       References:",
"       <br>",
"        <ol>",
"         <li>",
"          Nabil N, Miner DJ, Amatruda JM. Methimazole: an alternative route of administration. J Clin Endocrinol Metab 1982; 54:180.",
"         </li>",
"         <li>",
"          Walter RM Jr, Bartle WR. Rectal administration of propylthiouracil in the treatment of Graves' disease. Am J Med 1990; 88:69.",
"         </li>",
"        </ol>",
"       </br>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16604=[""].join("\n");
var outline_f16_13_16604=null;
var title_f16_13_16605="Susceptibility of pneumococci";
var content_f16_13_16605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpretive breakpoints for Streptococcus pneumoniae for selected antibiotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Antibiotic",
"      </td>",
"      <td class=\"subtitle1\">",
"       Susceptible",
"      </td>",
"      <td class=\"subtitle1\">",
"       Intermediate",
"      </td>",
"      <td class=\"subtitle1\">",
"       Resistant",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\">",
"       Penicillin G (parenteral)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Meningitis",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;0.06 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       --",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;0.12 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Non-meningitis*",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;2 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       4 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;8 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Penicillin V (oral)*",
"      </td>",
"      <td>",
"       &le;0.06 mcg/mL",
"      </td>",
"      <td>",
"       0.12 to 1 mcg/mL",
"      </td>",
"      <td>",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Amoxicillin (non-meningitis)",
"      </td>",
"      <td>",
"       &le;2 mcg/mL",
"      </td>",
"      <td>",
"       4 mcg/mL",
"      </td>",
"      <td>",
"       &ge;8 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Cefuroxime",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Parenteral",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;0.5 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       1 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Oral",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;1 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       2 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;4 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\" colspan=\"4\" rowspan=\"1\">",
"       Cefotaxime, Ceftriaxone",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Meningitis",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;0.5 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       1 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       Non-meningitis",
"      </td>",
"      <td class=\"sublist_other\">",
"       &le;1 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       2 mcg/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       &ge;4 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefpodoxime",
"      </td>",
"      <td>",
"       &le;0.5 mcg/mL",
"      </td>",
"      <td>",
"       1 mcg/mL",
"      </td>",
"      <td>",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cefdinir",
"      </td>",
"      <td>",
"       &le;0.5 mcg/mL",
"      </td>",
"      <td>",
"       1 mcg/mL",
"      </td>",
"      <td>",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clindamycin",
"      </td>",
"      <td>",
"       &le;0.25 mcg/mL",
"      </td>",
"      <td>",
"       0.5 mcg/mL",
"      </td>",
"      <td>",
"       &ge;1 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rifampin",
"      </td>",
"      <td>",
"       &le;1 mcg/mL",
"      </td>",
"      <td>",
"       2 mcg/mL",
"      </td>",
"      <td>",
"       &ge;4 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Azithromycin",
"      </td>",
"      <td>",
"       &le;0.5 mcg/mL",
"      </td>",
"      <td>",
"       1 mcg/mL",
"      </td>",
"      <td>",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Clarithromycin",
"      </td>",
"      <td>",
"       &le;0.25 mcg/mL",
"      </td>",
"      <td>",
"       0.5 mcg/mL",
"      </td>",
"      <td>",
"       &ge;2 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Gemifloxacin",
"      </td>",
"      <td>",
"       &le;0.12 mcg/mL",
"      </td>",
"      <td>",
"       0.25 mcg/mL",
"      </td>",
"      <td>",
"       &ge;0.5 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Levofloxacin",
"      </td>",
"      <td>",
"       &le;2 mcg/mL",
"      </td>",
"      <td>",
"       4 mcg/mL",
"      </td>",
"      <td>",
"       &ge;8 mcg/mL",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moxifloxacin",
"      </td>",
"      <td>",
"       &le;1 mcg/mL",
"      </td>",
"      <td>",
"       2 mcg/mL",
"      </td>",
"      <td>",
"       &ge;4 mcg/mL",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For non-meningitis isolates, the penicillin MIC can predict susceptibility to other beta-lactams as follows:",
"     <br>",
"      Penicillin MICs &le;0.06 mcg/mL indicate susceptibility to ampicillin (oral or parenteral), ampicillin-sulbactam, cefaclor, cefdinir, cefditoren, cefpodoxime, cefprozil, ceftizoxime, cefuroxime, imipenem, loracarbef, and meropenem.",
"      <br>",
"       Penicillin MICs &le;2 mcg/mL indicate susceptibility to amoxicillin, amoxicillin-clavulanate, cefepime, cefotaxime, ceftriaxone, and ertapenem.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Nineteenth Informational Supplement. CLSI document M100-S19. Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, PA 19087, USA, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16605=[""].join("\n");
var outline_f16_13_16605=null;
var title_f16_13_16606="Survival AML cytogenetic risk";
var content_f16_13_16606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65190&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Overall survival in acute myeloid leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure illustrates overall survival in adult subjects with acute myeloid leukemia (AML, age range 15 to 86 years, median 52 years), according to the following cytogenetic risk categories: Favorable risk (median survival 7.6 years): t(8;21); inv(16) or t(16;16); del(9q). Intermediate risk (median survival 1.3 years): normal karyotype; -Y; del(5q); loss of 7q; t(9;11); +11; del(11q); abn(12p); +13; del(20q); +21. Adverse risk (median survival 0.5 years): complex karyotype (&ge;3 abnormalities); inv(3) or t(3;3); t(6;9); t(6;11); -7; +8 (sole abnormality); +8 with one other abnormality other than t(8;21), t(9;11), inv(16), or t(16;16); t(11;19)(q23;p13.1).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Byrd, JC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8641). Blood 2002; 100:4325.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16606=[""].join("\n");
var outline_f16_13_16606=null;
var title_f16_13_16607="Infant mortality based on race and ethnicity of mother";
var content_f16_13_16607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 652px\">",
"   <div class=\"ttl\">",
"    Infant mortality rates by race and ethnicity of mother: United States, 2005 and 2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 632px; height: 482px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Significant decline.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Includes persons of Hispanic and non-Hispanic origin.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Matthews TJ, MacDorman MF. Infant mortality statistics from the 2009 period linked birth/infant death data set. Natl Vital Stat Rep 2013; 61:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_13_16607=[""].join("\n");
var outline_f16_13_16607=null;
